AU2002341881B2 - 3-(arylamino)methylene-1, 3-dihydro-2h-indol-2-ones as kinase inhibitors - Google Patents
3-(arylamino)methylene-1, 3-dihydro-2h-indol-2-ones as kinase inhibitors Download PDFInfo
- Publication number
- AU2002341881B2 AU2002341881B2 AU2002341881A AU2002341881A AU2002341881B2 AU 2002341881 B2 AU2002341881 B2 AU 2002341881B2 AU 2002341881 A AU2002341881 A AU 2002341881A AU 2002341881 A AU2002341881 A AU 2002341881A AU 2002341881 B2 AU2002341881 B2 AU 2002341881B2
- Authority
- AU
- Australia
- Prior art keywords
- indol
- methylene
- fluoro
- dihydro
- phenylamino
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 229940043355 kinase inhibitor Drugs 0.000 title description 3
- 239000003757 phosphotransferase inhibitor Substances 0.000 title description 3
- -1 ethyloxy, propyloxy, butyloxy, ethyl amino, propylamino Chemical group 0.000 claims description 225
- 150000001875 compounds Chemical class 0.000 claims description 166
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 38
- 238000000034 method Methods 0.000 claims description 32
- 208000035475 disorder Diseases 0.000 claims description 24
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 claims description 20
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 claims description 20
- 230000002062 proliferating effect Effects 0.000 claims description 15
- 201000010099 disease Diseases 0.000 claims description 14
- 125000001153 fluoro group Chemical group F* 0.000 claims description 12
- 206010028980 Neoplasm Diseases 0.000 claims description 11
- 201000011510 cancer Diseases 0.000 claims description 10
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 10
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims description 10
- 125000003545 alkoxy group Chemical group 0.000 claims description 9
- 125000005647 linker group Chemical group 0.000 claims description 9
- 210000004204 blood vessel Anatomy 0.000 claims description 8
- 125000002757 morpholinyl group Chemical group 0.000 claims description 8
- 239000003814 drug Substances 0.000 claims description 7
- 230000003176 fibrotic effect Effects 0.000 claims description 7
- 208000030159 metabolic disease Diseases 0.000 claims description 7
- 125000004193 piperazinyl group Chemical group 0.000 claims description 7
- 201000004681 Psoriasis Diseases 0.000 claims description 6
- 210000003584 mesangial cell Anatomy 0.000 claims description 6
- 239000008194 pharmaceutical composition Substances 0.000 claims description 6
- 206010012689 Diabetic retinopathy Diseases 0.000 claims description 5
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 5
- 201000001320 Atherosclerosis Diseases 0.000 claims description 4
- 125000003282 alkyl amino group Chemical group 0.000 claims description 4
- 206010003246 arthritis Diseases 0.000 claims description 4
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 claims description 4
- 208000002780 macular degeneration Diseases 0.000 claims description 4
- 206010038933 Retinopathy of prematurity Diseases 0.000 claims description 3
- 206010052779 Transplant rejections Diseases 0.000 claims description 3
- 206010064930 age-related macular degeneration Diseases 0.000 claims description 3
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 3
- 206010012601 diabetes mellitus Diseases 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
- 125000003386 piperidinyl group Chemical group 0.000 claims description 3
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 3
- 208000037803 restenosis Diseases 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 125000006309 butyl amino group Chemical group 0.000 claims 3
- 206010063209 Chronic allograft nephropathy Diseases 0.000 claims 2
- 206010018364 Glomerulonephritis Diseases 0.000 claims 2
- 206010061218 Inflammation Diseases 0.000 claims 2
- 208000034841 Thrombotic Microangiopathies Diseases 0.000 claims 2
- 208000031737 Tissue Adhesions Diseases 0.000 claims 2
- 208000019425 cirrhosis of liver Diseases 0.000 claims 2
- 230000004054 inflammatory process Effects 0.000 claims 2
- 230000003211 malignant effect Effects 0.000 claims 2
- 201000009925 nephrosclerosis Diseases 0.000 claims 2
- 230000004770 neurodegeneration Effects 0.000 claims 2
- 208000015122 neurodegenerative disease Diseases 0.000 claims 2
- 208000011580 syndromic disease Diseases 0.000 claims 2
- 230000029663 wound healing Effects 0.000 claims 2
- 208000007342 Diabetic Nephropathies Diseases 0.000 claims 1
- 208000032131 Diabetic Neuropathies Diseases 0.000 claims 1
- 125000004106 butoxy group Chemical group [*]OC([H])([H])C([H])([H])C(C([H])([H])[H])([H])[H] 0.000 claims 1
- 208000033679 diabetic kidney disease Diseases 0.000 claims 1
- JYGFTBXVXVMTGB-UHFFFAOYSA-N indolin-2-one Chemical compound C1=CC=C2NC(=O)CC2=C1 JYGFTBXVXVMTGB-UHFFFAOYSA-N 0.000 description 199
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 125
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 92
- 239000007787 solid Substances 0.000 description 86
- 239000011541 reaction mixture Substances 0.000 description 83
- 238000006243 chemical reaction Methods 0.000 description 64
- 239000000243 solution Substances 0.000 description 59
- 238000003556 assay Methods 0.000 description 56
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 45
- 235000019439 ethyl acetate Nutrition 0.000 description 45
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 44
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 42
- 239000005977 Ethylene Substances 0.000 description 38
- 229940093470 ethylene Drugs 0.000 description 38
- 239000003921 oil Substances 0.000 description 33
- 235000019198 oils Nutrition 0.000 description 33
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 31
- 238000001914 filtration Methods 0.000 description 30
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 30
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 30
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 29
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 29
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 29
- 239000002285 corn oil Substances 0.000 description 28
- 235000005687 corn oil Nutrition 0.000 description 28
- 238000010992 reflux Methods 0.000 description 27
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 26
- UORVGPXVDQYIDP-UHFFFAOYSA-N borane Chemical compound B UORVGPXVDQYIDP-UHFFFAOYSA-N 0.000 description 24
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 23
- 102000005962 receptors Human genes 0.000 description 23
- 108091008598 receptor tyrosine kinases Proteins 0.000 description 22
- 125000000217 alkyl group Chemical group 0.000 description 21
- 230000005764 inhibitory process Effects 0.000 description 21
- 239000012044 organic layer Substances 0.000 description 20
- 108020003175 receptors Proteins 0.000 description 20
- 102000027426 receptor tyrosine kinases Human genes 0.000 description 19
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 18
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 18
- 125000001309 chloro group Chemical group Cl* 0.000 description 18
- 238000002360 preparation method Methods 0.000 description 18
- 230000019491 signal transduction Effects 0.000 description 18
- 238000001704 evaporation Methods 0.000 description 17
- 230000008020 evaporation Effects 0.000 description 17
- 239000000725 suspension Substances 0.000 description 17
- 238000001665 trituration Methods 0.000 description 17
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 16
- 238000001816 cooling Methods 0.000 description 16
- 239000000203 mixture Substances 0.000 description 16
- 238000000935 solvent evaporation Methods 0.000 description 16
- 238000006467 substitution reaction Methods 0.000 description 16
- 125000003118 aryl group Chemical group 0.000 description 15
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 14
- 125000002490 anilino group Chemical group [H]N(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 14
- JLFNLZLINWHATN-UHFFFAOYSA-N pentaethylene glycol Chemical compound OCCOCCOCCOCCOCCO JLFNLZLINWHATN-UHFFFAOYSA-N 0.000 description 14
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 13
- 229920006395 saturated elastomer Polymers 0.000 description 13
- 239000000758 substrate Substances 0.000 description 13
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 12
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 description 12
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 12
- 229910000085 borane Inorganic materials 0.000 description 12
- 239000011575 calcium Substances 0.000 description 12
- 239000010410 layer Substances 0.000 description 12
- 238000010898 silica gel chromatography Methods 0.000 description 12
- 239000007868 Raney catalyst Substances 0.000 description 11
- 229910000564 Raney nickel Inorganic materials 0.000 description 11
- 108010053099 Vascular Endothelial Growth Factor Receptor-2 Proteins 0.000 description 11
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 description 11
- 229910052739 hydrogen Inorganic materials 0.000 description 11
- 239000002904 solvent Substances 0.000 description 11
- 125000001424 substituent group Chemical group 0.000 description 11
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 10
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 10
- 229910052736 halogen Inorganic materials 0.000 description 10
- 102000037979 non-receptor tyrosine kinases Human genes 0.000 description 10
- 108091008046 non-receptor tyrosine kinases Proteins 0.000 description 10
- 208000005590 Choroidal Neovascularization Diseases 0.000 description 9
- 206010060823 Choroidal neovascularisation Diseases 0.000 description 9
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 9
- 210000004027 cell Anatomy 0.000 description 9
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 9
- 239000003446 ligand Substances 0.000 description 9
- 125000004200 2-methoxyethyl group Chemical group [H]C([H])([H])OC([H])([H])C([H])([H])* 0.000 description 8
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 8
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 8
- 239000007864 aqueous solution Substances 0.000 description 8
- 239000012043 crude product Substances 0.000 description 8
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 8
- 239000007789 gas Substances 0.000 description 8
- 150000002367 halogens Chemical class 0.000 description 8
- IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine hydrate Chemical compound O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 8
- 125000001183 hydrocarbyl group Chemical group 0.000 description 8
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 8
- 239000002953 phosphate buffered saline Substances 0.000 description 8
- 230000026731 phosphorylation Effects 0.000 description 8
- 238000006366 phosphorylation reaction Methods 0.000 description 8
- JYGFTBXVXVMTGB-HOSYLAQJSA-N 1,3-dihydroindol-2-one Chemical class N1C([13CH2]C2=CC=CC=C12)=O JYGFTBXVXVMTGB-HOSYLAQJSA-N 0.000 description 7
- JVUCUNQXFYLSJI-UHFFFAOYSA-N 2-hydroxy-1H-indole-3-carbaldehyde Chemical compound C1=CC=C2C(C=O)=C(O)NC2=C1 JVUCUNQXFYLSJI-UHFFFAOYSA-N 0.000 description 7
- 239000012267 brine Substances 0.000 description 7
- 230000004663 cell proliferation Effects 0.000 description 7
- 125000004093 cyano group Chemical group *C#N 0.000 description 7
- 239000001257 hydrogen Substances 0.000 description 7
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 7
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 7
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 7
- 239000003981 vehicle Substances 0.000 description 7
- VMJNTFXCTXAXTC-UHFFFAOYSA-N 2,2-difluoro-1,3-benzodioxole-5-carbonitrile Chemical group C1=C(C#N)C=C2OC(F)(F)OC2=C1 VMJNTFXCTXAXTC-UHFFFAOYSA-N 0.000 description 6
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- 125000002877 alkyl aryl group Chemical group 0.000 description 6
- 239000000706 filtrate Substances 0.000 description 6
- 229920000728 polyester Polymers 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 230000001105 regulatory effect Effects 0.000 description 6
- 239000011734 sodium Substances 0.000 description 6
- UALFVGAUFYTZSV-ALCCZGGFSA-N (3z)-3-(hydroxymethylidene)-4-methyl-1h-indol-2-one Chemical compound CC1=CC=CC2=C1C(=C/O)/C(=O)N2 UALFVGAUFYTZSV-ALCCZGGFSA-N 0.000 description 5
- HNQLLEWMVJHVME-UHFFFAOYSA-N 3-(hydroxymethylidene)-6-(3-methoxyphenyl)-1h-indol-2-one Chemical compound COC1=CC=CC(C=2C=C3NC(=O)C(=CO)C3=CC=2)=C1 HNQLLEWMVJHVME-UHFFFAOYSA-N 0.000 description 5
- LLPIMIMXCXEFER-UHFFFAOYSA-N 4-(2-morpholin-4-ylethyl)aniline Chemical compound C1=CC(N)=CC=C1CCN1CCOCC1 LLPIMIMXCXEFER-UHFFFAOYSA-N 0.000 description 5
- VTBHKDHFDNLZNG-UHFFFAOYSA-N 4-(2-piperidin-1-ylethoxy)aniline Chemical compound C1=CC(N)=CC=C1OCCN1CCCCC1 VTBHKDHFDNLZNG-UHFFFAOYSA-N 0.000 description 5
- BUEFNCLNVXCFFS-UHFFFAOYSA-N 4-(2-piperidin-1-ylethyl)aniline Chemical compound C1=CC(N)=CC=C1CCN1CCCCC1 BUEFNCLNVXCFFS-UHFFFAOYSA-N 0.000 description 5
- ROPJHTWQKBBFTF-UHFFFAOYSA-N 4-(3-piperidin-1-ylpropoxy)aniline Chemical compound C1=CC(N)=CC=C1OCCCN1CCCCC1 ROPJHTWQKBBFTF-UHFFFAOYSA-N 0.000 description 5
- SALAKQGKZTZEDY-UHFFFAOYSA-N 4-(4-morpholin-4-ylbutyl)aniline Chemical compound C1=CC(N)=CC=C1CCCCN1CCOCC1 SALAKQGKZTZEDY-UHFFFAOYSA-N 0.000 description 5
- SSGNTACICQYKFJ-UHFFFAOYSA-N 4-n-(3-morpholin-4-ylpropyl)benzene-1,4-diamine Chemical compound C1=CC(N)=CC=C1NCCCN1CCOCC1 SSGNTACICQYKFJ-UHFFFAOYSA-N 0.000 description 5
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 5
- XBDQKXXYIPTUBI-UHFFFAOYSA-N Propionic acid Substances CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 5
- 240000008042 Zea mays Species 0.000 description 5
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 5
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 5
- 125000003342 alkenyl group Chemical group 0.000 description 5
- 125000000304 alkynyl group Chemical group 0.000 description 5
- 229910052799 carbon Inorganic materials 0.000 description 5
- 235000005822 corn Nutrition 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 239000011491 glass wool Substances 0.000 description 5
- 230000003834 intracellular effect Effects 0.000 description 5
- 229910052757 nitrogen Inorganic materials 0.000 description 5
- 229910052760 oxygen Inorganic materials 0.000 description 5
- 229920001223 polyethylene glycol Polymers 0.000 description 5
- 238000000746 purification Methods 0.000 description 5
- 230000004044 response Effects 0.000 description 5
- 150000003839 salts Chemical class 0.000 description 5
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 5
- 235000017557 sodium bicarbonate Nutrition 0.000 description 5
- 229910052717 sulfur Inorganic materials 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- YBADLXQNJCMBKR-UHFFFAOYSA-N (4-nitrophenyl)acetic acid Chemical compound OC(=O)CC1=CC=C([N+]([O-])=O)C=C1 YBADLXQNJCMBKR-UHFFFAOYSA-N 0.000 description 4
- VSMXLKGFTKFOSB-UHFFFAOYSA-N 1-ethyl-3h-indol-2-one Chemical compound C1=CC=C2N(CC)C(=O)CC2=C1 VSMXLKGFTKFOSB-UHFFFAOYSA-N 0.000 description 4
- WFQDTOYDVUWQMS-UHFFFAOYSA-N 1-fluoro-4-nitrobenzene Chemical compound [O-][N+](=O)C1=CC=C(F)C=C1 WFQDTOYDVUWQMS-UHFFFAOYSA-N 0.000 description 4
- GVNVAWHJIKLAGL-UHFFFAOYSA-N 2-(cyclohexen-1-yl)cyclohexan-1-one Chemical compound O=C1CCCCC1C1=CCCCC1 GVNVAWHJIKLAGL-UHFFFAOYSA-N 0.000 description 4
- WQMLUHZFRFCQDB-UHFFFAOYSA-N 4-(4-nitrophenyl)butyric acid Chemical compound OC(=O)CCCC1=CC=C([N+]([O-])=O)C=C1 WQMLUHZFRFCQDB-UHFFFAOYSA-N 0.000 description 4
- HNPYNSRMAAJEOG-UHFFFAOYSA-N 4-(4-piperidin-1-ylbutyl)aniline Chemical compound C1=CC(N)=CC=C1CCCCN1CCCCC1 HNPYNSRMAAJEOG-UHFFFAOYSA-N 0.000 description 4
- WNYFVEFUHMDIRQ-UHFFFAOYSA-N 4-(morpholin-4-ylmethyl)aniline Chemical compound C1=CC(N)=CC=C1CN1CCOCC1 WNYFVEFUHMDIRQ-UHFFFAOYSA-N 0.000 description 4
- MEMCCQUMSXPDPE-UHFFFAOYSA-N 4-n-[3-(4-methylpiperazin-1-yl)propyl]benzene-1,4-diamine Chemical compound C1CN(C)CCN1CCCNC1=CC=C(N)C=C1 MEMCCQUMSXPDPE-UHFFFAOYSA-N 0.000 description 4
- OTLNPYWUJOZPPA-UHFFFAOYSA-N 4-nitrobenzoic acid Chemical compound OC(=O)C1=CC=C([N+]([O-])=O)C=C1 OTLNPYWUJOZPPA-UHFFFAOYSA-N 0.000 description 4
- QHJCASNXAPQWFF-UHFFFAOYSA-N 6-fluoro-3-(hydroxymethylidene)-1h-indol-2-one Chemical compound FC1=CC=C2C(=CO)C(=O)NC2=C1 QHJCASNXAPQWFF-UHFFFAOYSA-N 0.000 description 4
- 239000005711 Benzoic acid Substances 0.000 description 4
- 101150065749 Churc1 gene Proteins 0.000 description 4
- 206010015866 Extravasation Diseases 0.000 description 4
- 102100038239 Protein Churchill Human genes 0.000 description 4
- 102000014400 SH2 domains Human genes 0.000 description 4
- 108050003452 SH2 domains Proteins 0.000 description 4
- 230000002159 abnormal effect Effects 0.000 description 4
- 125000004432 carbon atom Chemical group C* 0.000 description 4
- 230000001413 cellular effect Effects 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 230000036251 extravasation Effects 0.000 description 4
- 239000003102 growth factor Substances 0.000 description 4
- 230000003993 interaction Effects 0.000 description 4
- 230000003287 optical effect Effects 0.000 description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
- 230000011664 signaling Effects 0.000 description 4
- 230000000638 stimulation Effects 0.000 description 4
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 3
- UALFVGAUFYTZSV-UHFFFAOYSA-N 3-(hydroxymethylidene)-4-methyl-1h-indol-2-one Chemical compound CC1=CC=CC2=C1C(=CO)C(=O)N2 UALFVGAUFYTZSV-UHFFFAOYSA-N 0.000 description 3
- XMIIGOLPHOKFCH-UHFFFAOYSA-N 3-phenylpropionic acid Chemical compound OC(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-N 0.000 description 3
- GRSFQNVAPVZAOV-UHFFFAOYSA-N 4-[3-(diethylamino)propoxy]-3-fluoroaniline Chemical compound CCN(CC)CCCOC1=CC=C(N)C=C1F GRSFQNVAPVZAOV-UHFFFAOYSA-N 0.000 description 3
- WQQRLTZBDUWWAU-UHFFFAOYSA-N 4-[3-(diethylamino)propoxy]aniline Chemical compound CCN(CC)CCCOC1=CC=C(N)C=C1 WQQRLTZBDUWWAU-UHFFFAOYSA-N 0.000 description 3
- XYWIPYBIIRTJMM-IBGZPJMESA-N 4-[[(2S)-2-[4-[5-chloro-2-[4-(trifluoromethyl)triazol-1-yl]phenyl]-5-methoxy-2-oxopyridin-1-yl]butanoyl]amino]-2-fluorobenzamide Chemical compound CC[C@H](N1C=C(OC)C(=CC1=O)C1=C(C=CC(Cl)=C1)N1C=C(N=N1)C(F)(F)F)C(=O)NC1=CC(F)=C(C=C1)C(N)=O XYWIPYBIIRTJMM-IBGZPJMESA-N 0.000 description 3
- AGCYANRKPLCKEW-UHFFFAOYSA-N 4-fluoro-3-(hydroxymethylidene)-1h-indol-2-one Chemical compound C1=CC(F)=C2C(=CO)C(=O)NC2=C1 AGCYANRKPLCKEW-UHFFFAOYSA-N 0.000 description 3
- MIWXNKDIADESJW-UHFFFAOYSA-N 4-n-(2-morpholin-4-ylethyl)benzene-1,4-diamine Chemical compound C1=CC(N)=CC=C1NCCN1CCOCC1 MIWXNKDIADESJW-UHFFFAOYSA-N 0.000 description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
- 102000009465 Growth Factor Receptors Human genes 0.000 description 3
- 108010009202 Growth Factor Receptors Proteins 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 3
- 108091000080 Phosphotransferase Proteins 0.000 description 3
- 239000004698 Polyethylene Substances 0.000 description 3
- 229920001213 Polysorbate 20 Polymers 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 150000001412 amines Chemical class 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 description 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 3
- 230000003197 catalytic effect Effects 0.000 description 3
- 230000036755 cellular response Effects 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 125000004122 cyclic group Chemical group 0.000 description 3
- 230000001086 cytosolic effect Effects 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 230000004069 differentiation Effects 0.000 description 3
- UAOMVDZJSHZZME-UHFFFAOYSA-N diisopropylamine Chemical compound CC(C)NC(C)C UAOMVDZJSHZZME-UHFFFAOYSA-N 0.000 description 3
- 238000004090 dissolution Methods 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- 229910052731 fluorine Inorganic materials 0.000 description 3
- 125000005843 halogen group Chemical group 0.000 description 3
- 235000011167 hydrochloric acid Nutrition 0.000 description 3
- QNLOWBMKUIXCOW-UHFFFAOYSA-N indol-2-one Chemical compound C1=CC=CC2=NC(=O)C=C21 QNLOWBMKUIXCOW-UHFFFAOYSA-N 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 230000002503 metabolic effect Effects 0.000 description 3
- 239000012074 organic phase Substances 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 102000020233 phosphotransferase Human genes 0.000 description 3
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 3
- 125000006413 ring segment Chemical group 0.000 description 3
- 239000000741 silica gel Substances 0.000 description 3
- 229910002027 silica gel Inorganic materials 0.000 description 3
- 239000002002 slurry Substances 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 239000011593 sulfur Substances 0.000 description 3
- 150000003568 thioethers Chemical class 0.000 description 3
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 3
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 description 3
- 239000005483 tyrosine kinase inhibitor Substances 0.000 description 3
- CAKBAYWOHIUVHR-UHFFFAOYSA-N (4-nitrophenyl)-piperidin-1-ylmethanone Chemical compound C1=CC([N+](=O)[O-])=CC=C1C(=O)N1CCCCC1 CAKBAYWOHIUVHR-UHFFFAOYSA-N 0.000 description 2
- PAMJENUKCYUKLC-UHFFFAOYSA-N 1-(4-nitrobenzyl)piperidine Chemical compound C1=CC([N+](=O)[O-])=CC=C1CN1CCCCC1 PAMJENUKCYUKLC-UHFFFAOYSA-N 0.000 description 2
- QAFODUGVXFNLBE-UHFFFAOYSA-N 1-methoxybutan-2-amine Chemical compound CCC(N)COC QAFODUGVXFNLBE-UHFFFAOYSA-N 0.000 description 2
- XEWJEPSXWNILMA-UHFFFAOYSA-N 1-morpholin-4-yl-2-(4-nitrophenyl)ethanone Chemical compound C1=CC([N+](=O)[O-])=CC=C1CC(=O)N1CCOCC1 XEWJEPSXWNILMA-UHFFFAOYSA-N 0.000 description 2
- QDIMLTACZGGYHK-UHFFFAOYSA-N 1-morpholin-4-yl-4-(4-nitrophenyl)butan-1-one Chemical compound C1=CC([N+](=O)[O-])=CC=C1CCCC(=O)N1CCOCC1 QDIMLTACZGGYHK-UHFFFAOYSA-N 0.000 description 2
- ZUUQKDDUUOFCNP-UHFFFAOYSA-N 2-(1,3-dioxolan-2-yl)-n-methylethanamine Chemical compound CNCCC1OCCO1 ZUUQKDDUUOFCNP-UHFFFAOYSA-N 0.000 description 2
- FDMKTLRBJSCSDE-UHFFFAOYSA-N 2-(4-nitrophenyl)-1-piperidin-1-ylethanone Chemical compound C1=CC([N+](=O)[O-])=CC=C1CC(=O)N1CCCCC1 FDMKTLRBJSCSDE-UHFFFAOYSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- UHFXANYMAIRBOF-UHFFFAOYSA-N 2-[4-(3-methoxyphenyl)-2-nitrophenyl]acetic acid Chemical compound COC1=CC=CC(C=2C=C(C(CC(O)=O)=CC=2)[N+]([O-])=O)=C1 UHFXANYMAIRBOF-UHFFFAOYSA-N 0.000 description 2
- WKCYFSZDBICRKL-UHFFFAOYSA-N 3-(diethylamino)propan-1-ol Chemical compound CCN(CC)CCCO WKCYFSZDBICRKL-UHFFFAOYSA-N 0.000 description 2
- SHBOEOYGYJZCNX-UHFFFAOYSA-N 3-[[4-(3-iodopropoxy)anilino]methylidene]-1h-indol-2-one Chemical compound C1=CC(OCCCI)=CC=C1NC=C1C2=CC=CC=C2NC1=O SHBOEOYGYJZCNX-UHFFFAOYSA-N 0.000 description 2
- 125000004364 3-pyrrolinyl group Chemical group [H]C1=C([H])C([H])([H])N(*)C1([H])[H] 0.000 description 2
- OTYZNDKWNPQQJP-UHFFFAOYSA-N 4-(2-pyrrolidin-1-ylethoxy)aniline Chemical compound C1=CC(N)=CC=C1OCCN1CCCC1 OTYZNDKWNPQQJP-UHFFFAOYSA-N 0.000 description 2
- INYFDQFEQGCBSN-UHFFFAOYSA-N 4-(4-nitrophenyl)-1-piperidin-1-ylbutan-1-one Chemical compound C1=CC([N+](=O)[O-])=CC=C1CCCC(=O)N1CCCCC1 INYFDQFEQGCBSN-UHFFFAOYSA-N 0.000 description 2
- GFFZFWAUXAFCSY-UHFFFAOYSA-N 4-[2-(4-nitrophenyl)ethyl]morpholine Chemical compound C1=CC([N+](=O)[O-])=CC=C1CCN1CCOCC1 GFFZFWAUXAFCSY-UHFFFAOYSA-N 0.000 description 2
- LOLWRQUUOLPVOX-UHFFFAOYSA-N 4-[4-(4-nitrophenyl)butyl]morpholine Chemical compound C1=CC([N+](=O)[O-])=CC=C1CCCCN1CCOCC1 LOLWRQUUOLPVOX-UHFFFAOYSA-N 0.000 description 2
- IRQBUMYFAYXEGV-UHFFFAOYSA-N 6-(3-methoxyphenyl)-1,3-dihydroindol-2-one Chemical compound COC1=CC=CC(C=2C=C3NC(=O)CC3=CC=2)=C1 IRQBUMYFAYXEGV-UHFFFAOYSA-N 0.000 description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- KHBQMWCZKVMBLN-UHFFFAOYSA-N Benzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=CC=C1 KHBQMWCZKVMBLN-UHFFFAOYSA-N 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 208000005623 Carcinogenesis Diseases 0.000 description 2
- 201000009030 Carcinoma Diseases 0.000 description 2
- 241000700198 Cavia Species 0.000 description 2
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 2
- 206010039491 Sarcoma Diseases 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 239000004280 Sodium formate Substances 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 229910010062 TiCl3 Inorganic materials 0.000 description 2
- KPCZJLGGXRGYIE-UHFFFAOYSA-N [C]1=CC=CN=C1 Chemical group [C]1=CC=CN=C1 KPCZJLGGXRGYIE-UHFFFAOYSA-N 0.000 description 2
- 150000001408 amides Chemical class 0.000 description 2
- 125000000539 amino acid group Chemical group 0.000 description 2
- 150000001413 amino acids Chemical group 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000033115 angiogenesis Effects 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- JFDZBHWFFUWGJE-UHFFFAOYSA-N benzonitrile Substances N#CC1=CC=CC=C1 JFDZBHWFFUWGJE-UHFFFAOYSA-N 0.000 description 2
- 230000005587 bubbling Effects 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 230000036952 cancer formation Effects 0.000 description 2
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 2
- 231100000504 carcinogenesis Toxicity 0.000 description 2
- 230000024245 cell differentiation Effects 0.000 description 2
- 230000032823 cell division Effects 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 238000006471 dimerization reaction Methods 0.000 description 2
- KEGXRXDQFPQJPZ-UHFFFAOYSA-N dimethyl 2-[4-(3-methoxyphenyl)-2-nitrophenyl]propanedioate Chemical compound C1=C([N+]([O-])=O)C(C(C(=O)OC)C(=O)OC)=CC=C1C1=CC=CC(OC)=C1 KEGXRXDQFPQJPZ-UHFFFAOYSA-N 0.000 description 2
- 210000002889 endothelial cell Anatomy 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- AEOCXXJPGCBFJA-UHFFFAOYSA-N ethionamide Chemical compound CCC1=CC(C(N)=S)=CC=N1 AEOCXXJPGCBFJA-UHFFFAOYSA-N 0.000 description 2
- WBJINCZRORDGAQ-UHFFFAOYSA-N formic acid ethyl ester Natural products CCOC=O WBJINCZRORDGAQ-UHFFFAOYSA-N 0.000 description 2
- 208000005017 glioblastoma Diseases 0.000 description 2
- 125000005842 heteroatom Chemical group 0.000 description 2
- 150000002431 hydrogen Chemical class 0.000 description 2
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 230000031146 intracellular signal transduction Effects 0.000 description 2
- 125000004594 isoindolinyl group Chemical group C1(NCC2=CC=CC=C12)* 0.000 description 2
- 208000032839 leukemia Diseases 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- RZVWBASHHLFBJF-UHFFFAOYSA-N methyl piperidine-4-carboxylate Chemical compound COC(=O)C1CCNCC1 RZVWBASHHLFBJF-UHFFFAOYSA-N 0.000 description 2
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- OFSUBZOEFLPRFA-UHFFFAOYSA-N n,n-diethyl-3-(4-nitrophenoxy)propan-1-amine Chemical compound CCN(CC)CCCOC1=CC=C([N+]([O-])=O)C=C1 OFSUBZOEFLPRFA-UHFFFAOYSA-N 0.000 description 2
- NWUVRJDVZZNZGH-UHFFFAOYSA-N n-(2-morpholin-4-ylethyl)-4-nitroaniline Chemical compound C1=CC([N+](=O)[O-])=CC=C1NCCN1CCOCC1 NWUVRJDVZZNZGH-UHFFFAOYSA-N 0.000 description 2
- JHPKICVISZEWHB-UHFFFAOYSA-N n-(3-morpholin-4-ylpropyl)-4-nitroaniline Chemical compound C1=CC([N+](=O)[O-])=CC=C1NCCCN1CCOCC1 JHPKICVISZEWHB-UHFFFAOYSA-N 0.000 description 2
- KBBUZGTXUQJPEZ-UHFFFAOYSA-N n-(piperidin-1-ylmethyl)aniline Chemical compound C1CCCCN1CNC1=CC=CC=C1 KBBUZGTXUQJPEZ-UHFFFAOYSA-N 0.000 description 2
- RWIVICVCHVMHMU-UHFFFAOYSA-N n-aminoethylmorpholine Chemical compound NCCN1CCOCC1 RWIVICVCHVMHMU-UHFFFAOYSA-N 0.000 description 2
- AHVQYHFYQWKUKB-UHFFFAOYSA-N oxan-4-amine Chemical compound NC1CCOCC1 AHVQYHFYQWKUKB-UHFFFAOYSA-N 0.000 description 2
- IPBPLHNLRKRLPJ-UHFFFAOYSA-N oxan-4-ylmethanamine Chemical compound NCC1CCOCC1 IPBPLHNLRKRLPJ-UHFFFAOYSA-N 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- DCWXELXMIBXGTH-QMMMGPOBSA-N phosphonotyrosine Chemical group OC(=O)[C@@H](N)CC1=CC=C(OP(O)(O)=O)C=C1 DCWXELXMIBXGTH-QMMMGPOBSA-N 0.000 description 2
- 125000004437 phosphorous atom Chemical group 0.000 description 2
- 229910052698 phosphorus Inorganic materials 0.000 description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000011533 pre-incubation Methods 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 235000019260 propionic acid Nutrition 0.000 description 2
- 125000006514 pyridin-2-ylmethyl group Chemical group [H]C1=C([H])C([H])=C([H])C(=N1)C([H])([H])* 0.000 description 2
- 125000004076 pyridyl group Chemical group 0.000 description 2
- 238000001953 recrystallisation Methods 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 229960004889 salicylic acid Drugs 0.000 description 2
- HLBBKKJFGFRGMU-UHFFFAOYSA-M sodium formate Chemical compound [Na+].[O-]C=O HLBBKKJFGFRGMU-UHFFFAOYSA-M 0.000 description 2
- 235000019254 sodium formate Nutrition 0.000 description 2
- 229910052938 sodium sulfate Inorganic materials 0.000 description 2
- 235000011152 sodium sulphate Nutrition 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 2
- BRNULMACUQOKMR-UHFFFAOYSA-N thiomorpholine Chemical compound C1CSCCN1 BRNULMACUQOKMR-UHFFFAOYSA-N 0.000 description 2
- 125000004568 thiomorpholinyl group Chemical group 0.000 description 2
- YONPGGFAJWQGJC-UHFFFAOYSA-K titanium(iii) chloride Chemical compound Cl[Ti](Cl)Cl YONPGGFAJWQGJC-UHFFFAOYSA-K 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- 230000026683 transduction Effects 0.000 description 2
- 238000010361 transduction Methods 0.000 description 2
- 230000001052 transient effect Effects 0.000 description 2
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 2
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 2
- 229930195735 unsaturated hydrocarbon Natural products 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- 230000004862 vasculogenesis Effects 0.000 description 2
- DOMQFIFVDIAOOT-ROUUACIJSA-N (2S,3R)-N-[4-(2,6-dimethoxyphenyl)-5-(5-methylpyridin-3-yl)-1,2,4-triazol-3-yl]-3-(5-methylpyrimidin-2-yl)butane-2-sulfonamide Chemical compound COC1=C(C(=CC=C1)OC)N1C(=NN=C1C=1C=NC=C(C=1)C)NS(=O)(=O)[C@@H](C)[C@H](C)C1=NC=C(C=N1)C DOMQFIFVDIAOOT-ROUUACIJSA-N 0.000 description 1
- NLLGFYPSWCMUIV-UHFFFAOYSA-N (3-methoxyphenyl)boronic acid Chemical compound COC1=CC=CC(B(O)O)=C1 NLLGFYPSWCMUIV-UHFFFAOYSA-N 0.000 description 1
- RUBQQRMAWLSCCJ-UHFFFAOYSA-N 1,2-difluoro-4-nitrobenzene Chemical compound [O-][N+](=O)C1=CC=C(F)C(F)=C1 RUBQQRMAWLSCCJ-UHFFFAOYSA-N 0.000 description 1
- FAYAYUOZWYJNBD-UHFFFAOYSA-N 1,3-benzothiazol-6-amine Chemical compound NC1=CC=C2N=CSC2=C1 FAYAYUOZWYJNBD-UHFFFAOYSA-N 0.000 description 1
- XMFAAIVNNSITSV-UHFFFAOYSA-N 1,3-dihydropyrrol-3-ide Chemical compound C1=CNC=[C-]1 XMFAAIVNNSITSV-UHFFFAOYSA-N 0.000 description 1
- ZCCPVTVGEQLONB-UHFFFAOYSA-N 1-(1,3-dioxolan-2-yl)-n-methylmethanamine Chemical compound CNCC1OCCO1 ZCCPVTVGEQLONB-UHFFFAOYSA-N 0.000 description 1
- HLQQRQNEDYOBHS-UHFFFAOYSA-N 1-(2-(4-nitrophenoxy)ethyl)piperidine Chemical compound C1=CC([N+](=O)[O-])=CC=C1OCCN1CCCCC1 HLQQRQNEDYOBHS-UHFFFAOYSA-N 0.000 description 1
- PVOAHINGSUIXLS-UHFFFAOYSA-N 1-Methylpiperazine Chemical compound CN1CCNCC1 PVOAHINGSUIXLS-UHFFFAOYSA-N 0.000 description 1
- NYPUAPKNWBOVQV-UHFFFAOYSA-N 1-[2-(4-nitrophenyl)ethyl]piperidine Chemical compound C1=CC([N+](=O)[O-])=CC=C1CCN1CCCCC1 NYPUAPKNWBOVQV-UHFFFAOYSA-N 0.000 description 1
- SHOACHLSUNLCNR-UHFFFAOYSA-N 1-[2-fluoro-4-[(4-fluoro-2-oxo-1h-indol-3-ylidene)methylamino]phenyl]piperidine-4-carboxamide Chemical compound C1CC(C(=O)N)CCN1C(C(=C1)F)=CC=C1NC=C1C2=C(F)C=CC=C2NC1=O SHOACHLSUNLCNR-UHFFFAOYSA-N 0.000 description 1
- NEBISXLIZLBVOM-UHFFFAOYSA-N 1-[2-fluoro-4-[(5-fluoro-2-oxo-1h-indol-3-ylidene)methylamino]phenyl]piperidine-3-carboxamide Chemical compound C1C(C(=O)N)CCCN1C(C(=C1)F)=CC=C1NC=C1C2=CC(F)=CC=C2NC1=O NEBISXLIZLBVOM-UHFFFAOYSA-N 0.000 description 1
- JANFCNJKKNPLFM-UHFFFAOYSA-N 1-[2-fluoro-4-[(6-fluoro-2-oxo-1h-indol-3-ylidene)methylamino]phenyl]piperidine-4-carboxamide Chemical compound C1CC(C(=O)N)CCN1C(C(=C1)F)=CC=C1NC=C1C2=CC=C(F)C=C2NC1=O JANFCNJKKNPLFM-UHFFFAOYSA-N 0.000 description 1
- KYKOWCKYVHRPBL-UHFFFAOYSA-N 1-[4-(4-nitrophenyl)butyl]piperidine Chemical compound C1=CC([N+](=O)[O-])=CC=C1CCCCN1CCCCC1 KYKOWCKYVHRPBL-UHFFFAOYSA-N 0.000 description 1
- RUFCVZGHZSZOSG-UHFFFAOYSA-N 1-[4-[(4-methyl-2-oxo-1h-indol-3-ylidene)methylamino]phenyl]piperidine-3-carboxamide Chemical compound C1=2C(C)=CC=CC=2NC(=O)C1=CNC(C=C1)=CC=C1N1CCCC(C(N)=O)C1 RUFCVZGHZSZOSG-UHFFFAOYSA-N 0.000 description 1
- GHBYIRDRDWMRMB-UHFFFAOYSA-N 1-[4-[(5-fluoro-2-oxo-1h-indol-3-ylidene)methylamino]-2-methylphenyl]piperidine-3-carboxamide Chemical compound CC1=CC(NC=C2C3=CC(F)=CC=C3NC2=O)=CC=C1N1CCCC(C(N)=O)C1 GHBYIRDRDWMRMB-UHFFFAOYSA-N 0.000 description 1
- AFJYZYSWHOQFFO-UHFFFAOYSA-N 1-[4-[(5-fluoro-2-oxo-1h-indol-3-ylidene)methylamino]-2-methylphenyl]piperidine-4-carboxamide Chemical compound CC1=CC(NC=C2C3=CC(F)=CC=C3NC2=O)=CC=C1N1CCC(C(N)=O)CC1 AFJYZYSWHOQFFO-UHFFFAOYSA-N 0.000 description 1
- CROBDHDIFXUGKM-UHFFFAOYSA-N 1-[4-[(6-fluoro-2-oxo-1h-indol-3-ylidene)methylamino]phenyl]piperidine-4-carboxamide Chemical compound C1CC(C(=O)N)CCN1C(C=C1)=CC=C1NC=C1C2=CC=C(F)C=C2NC1=O CROBDHDIFXUGKM-UHFFFAOYSA-N 0.000 description 1
- SCRXASNUPJPFGP-UHFFFAOYSA-N 1-fluoro-3h-indol-2-one Chemical compound C1=CC=C2N(F)C(=O)CC2=C1 SCRXASNUPJPFGP-UHFFFAOYSA-N 0.000 description 1
- UOXZPEGXZWCOPR-UHFFFAOYSA-N 1-fluoro-4-(3-methoxyphenyl)-2-nitrobenzene Chemical group COC1=CC=CC(C=2C=C(C(F)=CC=2)[N+]([O-])=O)=C1 UOXZPEGXZWCOPR-UHFFFAOYSA-N 0.000 description 1
- JQCSUVJDBHJKNG-UHFFFAOYSA-N 1-methoxy-ethyl Chemical group C[CH]OC JQCSUVJDBHJKNG-UHFFFAOYSA-N 0.000 description 1
- RSQUAQMIGSMNNE-UHFFFAOYSA-N 1-methyl-3h-indol-2-one Chemical compound C1=CC=C2N(C)C(=O)CC2=C1 RSQUAQMIGSMNNE-UHFFFAOYSA-N 0.000 description 1
- KAESVJOAVNADME-UHFFFAOYSA-N 1H-pyrrole Natural products C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 1
- PMYAWGSTXCVTTG-UHFFFAOYSA-N 2,2-dimethylpropyl [4-fluoro-2-methyl-5-[(2-oxo-1h-indol-3-ylidene)methylamino]phenyl] carbonate Chemical compound C1=C(OC(=O)OCC(C)(C)C)C(C)=CC(F)=C1NC=C1C2=CC=CC=C2NC1=O PMYAWGSTXCVTTG-UHFFFAOYSA-N 0.000 description 1
- ONUKJVAMEHIPPH-UHFFFAOYSA-N 2-(2,3-dihydropyrrol-1-yl)ethanol Chemical compound OCCN1CCC=C1 ONUKJVAMEHIPPH-UHFFFAOYSA-N 0.000 description 1
- KZTWONRVIPPDKH-UHFFFAOYSA-N 2-(piperidin-1-yl)ethanol Chemical compound OCCN1CCCCC1 KZTWONRVIPPDKH-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- RYCSNJCJOVQGBC-UHFFFAOYSA-N 3-(1-cyclopropyl-2h-pyridin-4-yl)-1h-quinolin-2-one Chemical class O=C1NC2=CC=CC=C2C=C1C(C=C1)=CCN1C1CC1 RYCSNJCJOVQGBC-UHFFFAOYSA-N 0.000 description 1
- RGUABPVONIGVAT-UHFFFAOYSA-N 3-(4-methylpiperazin-1-yl)propan-1-amine Chemical compound CN1CCN(CCCN)CC1 RGUABPVONIGVAT-UHFFFAOYSA-N 0.000 description 1
- KOBUXAQDZSROAT-UHFFFAOYSA-N 3-(phenyliminomethyl)-1H-indol-2-ol Chemical compound C1=CC=C(C=C1)N=CC2=C(NC3=CC=CC=C32)O KOBUXAQDZSROAT-UHFFFAOYSA-N 0.000 description 1
- RFJLNKXEXBWWJE-UHFFFAOYSA-N 3-[(3,4-dimethylanilino)methylidene]-4-methyl-1h-indol-2-one Chemical compound C1=2C(C)=CC=CC=2NC(=O)C1=CNC1=CC=C(C)C(C)=C1 RFJLNKXEXBWWJE-UHFFFAOYSA-N 0.000 description 1
- NOFVMKKJNXDMPJ-UHFFFAOYSA-N 3-[(3-aminoanilino)methylidene]-4-methyl-1h-indol-2-one Chemical compound C1=2C(C)=CC=CC=2NC(=O)C1=CNC1=CC=CC(N)=C1 NOFVMKKJNXDMPJ-UHFFFAOYSA-N 0.000 description 1
- BVKVAHHSTWVVKV-UHFFFAOYSA-N 3-[(3-bromoanilino)methyl]-1,3-dihydroindol-2-one Chemical compound BrC1=CC=CC(NCC2C3=CC=CC=C3NC2=O)=C1 BVKVAHHSTWVVKV-UHFFFAOYSA-N 0.000 description 1
- UAZMCJQRHOIAFV-UHFFFAOYSA-N 3-[(3-hydroxy-4-methylanilino)methylidene]-1h-indol-2-one Chemical compound C1=C(O)C(C)=CC=C1NC=C1C2=CC=CC=C2NC1=O UAZMCJQRHOIAFV-UHFFFAOYSA-N 0.000 description 1
- RELFFSHFPINMHV-UHFFFAOYSA-N 3-[(3-hydroxyanilino)methylidene]-1h-indol-2-one Chemical compound OC1=CC=CC(NC=C2C3=CC=CC=C3NC2=O)=C1 RELFFSHFPINMHV-UHFFFAOYSA-N 0.000 description 1
- CJHDIMICJVIKQS-UHFFFAOYSA-N 3-[(4-chloroanilino)methylidene]-1h-indol-2-one Chemical compound C1=CC(Cl)=CC=C1NC=C1C2=CC=CC=C2NC1=O CJHDIMICJVIKQS-UHFFFAOYSA-N 0.000 description 1
- OFFAZVPFZFWSMO-UHFFFAOYSA-N 3-[(4-ethoxyanilino)methylidene]-1h-indol-2-one Chemical compound C1=CC(OCC)=CC=C1NC=C1C2=CC=CC=C2NC1=O OFFAZVPFZFWSMO-UHFFFAOYSA-N 0.000 description 1
- JVCQDTZRXADEKM-UHFFFAOYSA-N 3-[(4-ethylanilino)methylidene]-4-methyl-1h-indol-2-one Chemical compound C1=CC(CC)=CC=C1NC=C1C2=C(C)C=CC=C2NC1=O JVCQDTZRXADEKM-UHFFFAOYSA-N 0.000 description 1
- CGZUYJPMUOAKAO-UHFFFAOYSA-N 3-[(4-hydroxyphenyl)iminomethyl]-1H-indol-2-ol Chemical compound OC1=CC=C(C=C1)N=CC1=C(NC2=CC=CC=C12)O CGZUYJPMUOAKAO-UHFFFAOYSA-N 0.000 description 1
- KSQJCLXMMKDHAV-UHFFFAOYSA-N 3-[(4-morpholin-4-ylanilino)methylidene]-5-nitro-1h-indol-2-one Chemical compound C12=CC([N+](=O)[O-])=CC=C2NC(=O)C1=CNC(C=C1)=CC=C1N1CCOCC1 KSQJCLXMMKDHAV-UHFFFAOYSA-N 0.000 description 1
- QELINEWLVXSZMI-UHFFFAOYSA-N 3-[(4-propan-2-ylanilino)methylidene]-1h-indol-2-one Chemical compound C1=CC(C(C)C)=CC=C1NC=C1C2=CC=CC=C2NC1=O QELINEWLVXSZMI-UHFFFAOYSA-N 0.000 description 1
- YGYGASJNJTYNOL-CQSZACIVSA-N 3-[(4r)-2,2-dimethyl-1,1-dioxothian-4-yl]-5-(4-fluorophenyl)-1h-indole-7-carboxamide Chemical compound C1CS(=O)(=O)C(C)(C)C[C@@H]1C1=CNC2=C(C(N)=O)C=C(C=3C=CC(F)=CC=3)C=C12 YGYGASJNJTYNOL-CQSZACIVSA-N 0.000 description 1
- LKHLKHRCYKIACR-UHFFFAOYSA-N 3-[[3-fluoro-4-(5-oxo-1,4-diazepan-1-yl)anilino]methylidene]-1h-indol-2-one Chemical compound FC1=CC(NC=C2C3=CC=CC=C3NC2=O)=CC=C1N1CCNC(=O)CC1 LKHLKHRCYKIACR-UHFFFAOYSA-N 0.000 description 1
- BIDXFHLRZVAEII-UHFFFAOYSA-N 3-[[3-fluoro-4-[(1,2,2,6,6-pentamethylpiperidin-4-yl)amino]anilino]methylidene]-1h-indol-2-one Chemical compound C1C(C)(C)N(C)C(C)(C)CC1NC(C(=C1)F)=CC=C1NC=C1C2=CC=CC=C2NC1=O BIDXFHLRZVAEII-UHFFFAOYSA-N 0.000 description 1
- NYAMXNVZNLCOBM-UHFFFAOYSA-N 3-[[3-fluoro-4-[2-methoxyethyl(propyl)amino]anilino]methylidene]-1h-indol-2-one Chemical compound C1=C(F)C(N(CCOC)CCC)=CC=C1NC=C1C2=CC=CC=C2NC1=O NYAMXNVZNLCOBM-UHFFFAOYSA-N 0.000 description 1
- XOOCXCCMKKOGCD-UHFFFAOYSA-N 3-[[3-methyl-4-(oxan-4-ylmethylamino)anilino]methylidene]-1h-indol-2-one Chemical compound CC1=CC(NC=C2C3=CC=CC=C3NC2=O)=CC=C1NCC1CCOCC1 XOOCXCCMKKOGCD-UHFFFAOYSA-N 0.000 description 1
- MFOXSDITRAOYLB-UHFFFAOYSA-N 3-[[4-(1-methoxypropan-2-ylamino)-3-(trifluoromethyl)anilino]methylidene]-4-methyl-1h-indol-2-one Chemical compound C1=C(C(F)(F)F)C(NC(C)COC)=CC=C1NC=C1C2=C(C)C=CC=C2NC1=O MFOXSDITRAOYLB-UHFFFAOYSA-N 0.000 description 1
- XRBJXPMFTJBVDL-UHFFFAOYSA-N 3-[[4-(1-methoxypropan-2-ylamino)anilino]methylidene]-1h-indol-2-one Chemical compound C1=CC(NC(C)COC)=CC=C1NC=C1C2=CC=CC=C2NC1=O XRBJXPMFTJBVDL-UHFFFAOYSA-N 0.000 description 1
- HTFMTQWTWSJCFE-UHFFFAOYSA-N 3-[[4-(2-hydroxyethyl)anilino]methylidene]-1h-indol-2-one Chemical compound C1=CC(CCO)=CC=C1NC=C1C2=CC=CC=C2NC1=O HTFMTQWTWSJCFE-UHFFFAOYSA-N 0.000 description 1
- DJTSOPOQJZPUMX-UHFFFAOYSA-N 3-[[4-(2-methoxyethylamino)-3-(trifluoromethyl)anilino]methylidene]-1h-indol-2-one Chemical compound C1=C(C(F)(F)F)C(NCCOC)=CC=C1NC=C1C2=CC=CC=C2NC1=O DJTSOPOQJZPUMX-UHFFFAOYSA-N 0.000 description 1
- BGRWJLDURCVAOY-UHFFFAOYSA-N 3-[[4-(2-methoxyethylamino)anilino]methylidene]-1h-indol-2-one Chemical compound C1=CC(NCCOC)=CC=C1NC=C1C2=CC=CC=C2NC1=O BGRWJLDURCVAOY-UHFFFAOYSA-N 0.000 description 1
- NVLIRQFALWXIQL-UHFFFAOYSA-N 3-[[4-(3,4,4a,5,6,7,8,8a-octahydro-1h-isoquinolin-2-yl)-3-(trifluoromethyl)anilino]methylidene]-4-fluoro-1h-indol-2-one Chemical compound C1CC2CCCCC2CN1C(C(=C1)C(F)(F)F)=CC=C1NC=C1C(=O)NC2=C1C(F)=CC=C2 NVLIRQFALWXIQL-UHFFFAOYSA-N 0.000 description 1
- PHRIUQSKFHJANS-UHFFFAOYSA-N 3-[[4-(4-iodobutoxy)anilino]methylidene]-1h-indol-2-one Chemical compound C1=CC(OCCCCI)=CC=C1NC=C1C2=CC=CC=C2NC1=O PHRIUQSKFHJANS-UHFFFAOYSA-N 0.000 description 1
- RRDYWTMDVBPHSP-UHFFFAOYSA-N 3-[[4-(4-morpholin-4-ylbutyl)anilino]methylidene]-1h-indol-2-one Chemical compound O=C1NC2=CC=CC=C2C1=CNC(C=C1)=CC=C1CCCCN1CCOCC1 RRDYWTMDVBPHSP-UHFFFAOYSA-N 0.000 description 1
- RGSVWLBPTBQRCJ-UHFFFAOYSA-N 3-[[4-(4-pyrrolidin-1-ylbutoxy)anilino]methylidene]-1h-indol-2-one Chemical compound O=C1NC2=CC=CC=C2C1=CNC(C=C1)=CC=C1OCCCCN1CCCC1 RGSVWLBPTBQRCJ-UHFFFAOYSA-N 0.000 description 1
- LRIFCCNWYXNDSH-UHFFFAOYSA-N 3-[[4-(azocan-1-yl)anilino]methylidene]-5-fluoro-1h-indol-2-one Chemical compound C12=CC(F)=CC=C2NC(=O)C1=CNC(C=C1)=CC=C1N1CCCCCCC1 LRIFCCNWYXNDSH-UHFFFAOYSA-N 0.000 description 1
- SZDYCJCJEJPDRT-UHFFFAOYSA-N 3-[[4-(diethylamino)-3-fluoroanilino]methylidene]-1h-indol-2-one Chemical compound C1=C(F)C(N(CC)CC)=CC=C1NC=C1C2=CC=CC=C2NC1=O SZDYCJCJEJPDRT-UHFFFAOYSA-N 0.000 description 1
- UQRIJGYLTIAVCC-UHFFFAOYSA-N 3-[[4-(diethylamino)-3-fluoroanilino]methylidene]-4-methyl-1h-indol-2-one Chemical compound C1=C(F)C(N(CC)CC)=CC=C1NC=C1C2=C(C)C=CC=C2NC1=O UQRIJGYLTIAVCC-UHFFFAOYSA-N 0.000 description 1
- IZFJLRWQDWJTOW-UHFFFAOYSA-N 3-[[4-(diethylamino)anilino]methylidene]-1h-indol-2-one Chemical compound C1=CC(N(CC)CC)=CC=C1NC=C1C2=CC=CC=C2NC1=O IZFJLRWQDWJTOW-UHFFFAOYSA-N 0.000 description 1
- UBXNQBCOROIYRJ-UHFFFAOYSA-N 3-[[4-(dipropylamino)-3-(trifluoromethyl)anilino]methylidene]-5-fluoro-1h-indol-2-one Chemical compound C1=C(C(F)(F)F)C(N(CCC)CCC)=CC=C1NC=C1C2=CC(F)=CC=C2NC1=O UBXNQBCOROIYRJ-UHFFFAOYSA-N 0.000 description 1
- KGRXYXFSLSDSLA-UHFFFAOYSA-N 3-[[4-(dipropylamino)-3-fluoroanilino]methylidene]-1h-indol-2-one Chemical compound C1=C(F)C(N(CCC)CCC)=CC=C1NC=C1C2=CC=CC=C2NC1=O KGRXYXFSLSDSLA-UHFFFAOYSA-N 0.000 description 1
- IQPRHEAGTLLRNB-UHFFFAOYSA-N 3-[[4-(dipropylamino)-3-fluoroanilino]methylidene]-6-fluoro-1h-indol-2-one Chemical compound C1=C(F)C(N(CCC)CCC)=CC=C1NC=C1C2=CC=C(F)C=C2NC1=O IQPRHEAGTLLRNB-UHFFFAOYSA-N 0.000 description 1
- CEIAGUWINUCEJO-UHFFFAOYSA-N 3-[[4-(morpholin-4-ylmethyl)anilino]methylidene]-1h-indol-2-one Chemical compound O=C1NC2=CC=CC=C2C1=CNC(C=C1)=CC=C1CN1CCOCC1 CEIAGUWINUCEJO-UHFFFAOYSA-N 0.000 description 1
- WCPCJSSJWMCJDV-UHFFFAOYSA-N 3-[[4-(oxan-4-ylmethylamino)-3-(trifluoromethyl)anilino]methylidene]-1h-indol-2-one Chemical compound FC(F)(F)C1=CC(NC=C2C3=CC=CC=C3NC2=O)=CC=C1NCC1CCOCC1 WCPCJSSJWMCJDV-UHFFFAOYSA-N 0.000 description 1
- KYKKCUBVPOUKPK-UHFFFAOYSA-N 3-[[4-(oxan-4-ylmethylamino)anilino]methylidene]-1h-indol-2-one Chemical compound O=C1NC2=CC=CC=C2C1=CNC(C=C1)=CC=C1NCC1CCOCC1 KYKKCUBVPOUKPK-UHFFFAOYSA-N 0.000 description 1
- FJBMLMLGTYOKIE-UHFFFAOYSA-N 3-[[4-(piperidin-1-ylmethyl)anilino]methylidene]-1h-indol-2-one Chemical compound O=C1NC2=CC=CC=C2C1=CNC(C=C1)=CC=C1CN1CCCCC1 FJBMLMLGTYOKIE-UHFFFAOYSA-N 0.000 description 1
- YPFOKKPDPSLOBS-UHFFFAOYSA-N 3-[[4-(pyridin-3-ylmethylamino)-3-(trifluoromethyl)anilino]methylidene]-1h-indol-2-one Chemical compound FC(F)(F)C1=CC(NC=C2C3=CC=CC=C3NC2=O)=CC=C1NCC1=CC=CN=C1 YPFOKKPDPSLOBS-UHFFFAOYSA-N 0.000 description 1
- CRLPHKSJPMACIS-UHFFFAOYSA-N 3-[[4-[(2,2-dimethyl-1,3-dioxolan-4-yl)methylamino]-3-methylanilino]methylidene]-4-fluoro-1h-indol-2-one Chemical compound CC1=CC(NC=C2C3=C(F)C=CC=C3NC2=O)=CC=C1NCC1COC(C)(C)O1 CRLPHKSJPMACIS-UHFFFAOYSA-N 0.000 description 1
- PPJZPQOAYORLRB-UHFFFAOYSA-N 3-[[4-[(5-methylpyrazin-2-yl)methylamino]-3-(trifluoromethyl)anilino]methylidene]-1h-indol-2-one Chemical compound C1=NC(C)=CN=C1CNC(C(=C1)C(F)(F)F)=CC=C1NC=C1C2=CC=CC=C2NC1=O PPJZPQOAYORLRB-UHFFFAOYSA-N 0.000 description 1
- STHVUPWABJOFHA-UHFFFAOYSA-N 3-[[4-[(5-methylpyrazin-2-yl)methylamino]anilino]methylidene]-1h-indol-2-one Chemical compound C1=NC(C)=CN=C1CNC(C=C1)=CC=C1NC=C1C2=CC=CC=C2NC1=O STHVUPWABJOFHA-UHFFFAOYSA-N 0.000 description 1
- ILWSVOLVALULGR-UHFFFAOYSA-N 3-[[4-[1-(diethylamino)propan-2-ylamino]-3-(trifluoromethyl)anilino]methylidene]-1h-indol-2-one Chemical compound C1=C(C(F)(F)F)C(NC(C)CN(CC)CC)=CC=C1NC=C1C2=CC=CC=C2NC1=O ILWSVOLVALULGR-UHFFFAOYSA-N 0.000 description 1
- MBFGQEHXHIWJJD-UHFFFAOYSA-N 3-[[4-[1-(dimethylamino)propan-2-ylamino]-3-(trifluoromethyl)anilino]methylidene]-1h-indol-2-one Chemical compound C1=C(C(F)(F)F)C(NC(CN(C)C)C)=CC=C1NC=C1C2=CC=CC=C2NC1=O MBFGQEHXHIWJJD-UHFFFAOYSA-N 0.000 description 1
- ZBEMCJBDWPHTAD-UHFFFAOYSA-N 3-[[4-[1-(dimethylamino)propan-2-ylamino]-3-(trifluoromethyl)anilino]methylidene]-5-fluoro-1h-indol-2-one Chemical compound C1=C(C(F)(F)F)C(NC(CN(C)C)C)=CC=C1NC=C1C2=CC(F)=CC=C2NC1=O ZBEMCJBDWPHTAD-UHFFFAOYSA-N 0.000 description 1
- KAQZNVVSCBAWDZ-UHFFFAOYSA-N 3-[[4-[1-(dimethylamino)propan-2-ylamino]-3-(trifluoromethyl)anilino]methylidene]-6-fluoro-1h-indol-2-one Chemical compound C1=C(C(F)(F)F)C(NC(CN(C)C)C)=CC=C1NC=C1C2=CC=C(F)C=C2NC1=O KAQZNVVSCBAWDZ-UHFFFAOYSA-N 0.000 description 1
- XPSWSOLAEOAREB-UHFFFAOYSA-N 3-[[4-[2-(diethylamino)ethylamino]-3-methylanilino]methylidene]-6-fluoro-1h-indol-2-one Chemical compound C1=C(C)C(NCCN(CC)CC)=CC=C1NC=C1C2=CC=C(F)C=C2NC1=O XPSWSOLAEOAREB-UHFFFAOYSA-N 0.000 description 1
- RFJLJHAXRIEXMP-UHFFFAOYSA-N 3-[[4-[2-(dimethylamino)ethylamino]-3-fluoroanilino]methylidene]-4-methyl-1h-indol-2-one Chemical compound C1=C(F)C(NCCN(C)C)=CC=C1NC=C1C2=C(C)C=CC=C2NC1=O RFJLJHAXRIEXMP-UHFFFAOYSA-N 0.000 description 1
- HTFMGCDXLQRSBO-UHFFFAOYSA-N 3-[[4-[2-methoxyethyl(methyl)amino]anilino]methylidene]-1h-indol-2-one Chemical compound C1=CC(N(C)CCOC)=CC=C1NC=C1C2=CC=CC=C2NC1=O HTFMGCDXLQRSBO-UHFFFAOYSA-N 0.000 description 1
- ZPFIFIVKFBSFIE-UHFFFAOYSA-N 3-[[4-[2-methoxyethyl(methyl)amino]anilino]methylidene]-4-methyl-1h-indol-2-one Chemical compound C1=CC(N(C)CCOC)=CC=C1NC=C1C2=C(C)C=CC=C2NC1=O ZPFIFIVKFBSFIE-UHFFFAOYSA-N 0.000 description 1
- PEBRQJOESXFUAV-UHFFFAOYSA-N 3-[[4-[2-methoxyethyl(propyl)amino]anilino]methylidene]-1h-indol-2-one Chemical compound C1=CC(N(CCOC)CCC)=CC=C1NC=C1C2=CC=CC=C2NC1=O PEBRQJOESXFUAV-UHFFFAOYSA-N 0.000 description 1
- SZSLQSPSICDSMY-UHFFFAOYSA-N 3-[[4-[3-(diethylamino)propoxy]-3-fluoroanilino]methylidene]-4-methyl-1h-indol-2-one Chemical compound C1=C(F)C(OCCCN(CC)CC)=CC=C1NC=C1C2=C(C)C=CC=C2NC1=O SZSLQSPSICDSMY-UHFFFAOYSA-N 0.000 description 1
- RSANIIVFTFENMG-UHFFFAOYSA-N 3-[[4-[3-(diethylamino)propylamino]-3-methylanilino]methylidene]-4-methyl-1h-indol-2-one Chemical compound C1=C(C)C(NCCCN(CC)CC)=CC=C1NC=C1C2=C(C)C=CC=C2NC1=O RSANIIVFTFENMG-UHFFFAOYSA-N 0.000 description 1
- ASFYJNVAZROEBF-UHFFFAOYSA-N 3-[[4-[3-(diethylamino)pyrrolidin-1-yl]anilino]methylidene]-4-fluoro-1h-indol-2-one Chemical compound C1C(N(CC)CC)CCN1C(C=C1)=CC=C1NC=C1C2=C(F)C=CC=C2NC1=O ASFYJNVAZROEBF-UHFFFAOYSA-N 0.000 description 1
- AJWBHRQIZLXFBD-UHFFFAOYSA-N 3-[[4-[3-(diethylamino)pyrrolidin-1-yl]anilino]methylidene]-6-fluoro-1h-indol-2-one Chemical compound C1C(N(CC)CC)CCN1C(C=C1)=CC=C1NC=C1C2=CC=C(F)C=C2NC1=O AJWBHRQIZLXFBD-UHFFFAOYSA-N 0.000 description 1
- NGAYCWGNVCPGGA-UHFFFAOYSA-N 3-[[4-[3-(dimethylamino)propylamino]-3-(trifluoromethyl)anilino]methylidene]-1h-indol-2-one Chemical compound C1=C(C(F)(F)F)C(NCCCN(C)C)=CC=C1NC=C1C2=CC=CC=C2NC1=O NGAYCWGNVCPGGA-UHFFFAOYSA-N 0.000 description 1
- FTRLVKILQVPTPV-UHFFFAOYSA-N 3-[[4-[3-(dimethylamino)propylamino]-3-fluoroanilino]methylidene]-1h-indol-2-one Chemical compound C1=C(F)C(NCCCN(C)C)=CC=C1NC=C1C2=CC=CC=C2NC1=O FTRLVKILQVPTPV-UHFFFAOYSA-N 0.000 description 1
- DDDZXXKUXUTRHQ-UHFFFAOYSA-N 3-[[4-[3-(dimethylamino)propylamino]-3-methylanilino]methylidene]-4-methyl-1h-indol-2-one Chemical compound C1=C(C)C(NCCCN(C)C)=CC=C1NC=C1C2=C(C)C=CC=C2NC1=O DDDZXXKUXUTRHQ-UHFFFAOYSA-N 0.000 description 1
- JFYZMTDWMKUAIH-UHFFFAOYSA-N 3-[[4-[4-(2-methoxyethyl)piperazin-1-yl]anilino]methylidene]-4-methyl-1h-indol-2-one Chemical compound C1CN(CCOC)CCN1C(C=C1)=CC=C1NC=C1C2=C(C)C=CC=C2NC1=O JFYZMTDWMKUAIH-UHFFFAOYSA-N 0.000 description 1
- GNVAPCXKIROSMQ-UHFFFAOYSA-N 3-[[4-[butyl(ethyl)amino]anilino]methylidene]-4-fluoro-1h-indol-2-one Chemical compound C1=CC(N(CC)CCCC)=CC=C1NC=C1C2=C(F)C=CC=C2NC1=O GNVAPCXKIROSMQ-UHFFFAOYSA-N 0.000 description 1
- ANIRIIWPRCONPE-UHFFFAOYSA-N 3-[[4-[butyl(propyl)amino]anilino]methylidene]-4-fluoro-1h-indol-2-one Chemical compound C1=CC(N(CCC)CCCC)=CC=C1NC=C1C2=C(F)C=CC=C2NC1=O ANIRIIWPRCONPE-UHFFFAOYSA-N 0.000 description 1
- WKQGKVGABBYGKB-UHFFFAOYSA-N 3-[[4-[cyclopropylmethyl(propyl)amino]-3-fluoroanilino]methylidene]-6-fluoro-1h-indol-2-one Chemical compound C=1C=C(NC=C2C3=CC=C(F)C=C3NC2=O)C=C(F)C=1N(CCC)CC1CC1 WKQGKVGABBYGKB-UHFFFAOYSA-N 0.000 description 1
- XNNRRSXTQFGEMQ-UHFFFAOYSA-N 3-[[4-[ethyl(2-methoxyethyl)amino]-3-(trifluoromethyl)anilino]methylidene]-4-fluoro-1h-indol-2-one Chemical compound C1=C(C(F)(F)F)C(N(CCOC)CC)=CC=C1NC=C1C2=C(F)C=CC=C2NC1=O XNNRRSXTQFGEMQ-UHFFFAOYSA-N 0.000 description 1
- IFMYMMZEXFAAQD-UHFFFAOYSA-N 3-[[4-[ethyl(2-methoxyethyl)amino]-3-fluoroanilino]methylidene]-4-methyl-1h-indol-2-one Chemical compound C1=C(F)C(N(CCOC)CC)=CC=C1NC=C1C2=C(C)C=CC=C2NC1=O IFMYMMZEXFAAQD-UHFFFAOYSA-N 0.000 description 1
- GMBWVUQXXBMVSA-UHFFFAOYSA-N 3-[[4-[ethyl(2-methoxyethyl)amino]anilino]methylidene]-4-methyl-1h-indol-2-one Chemical compound C1=CC(N(CCOC)CC)=CC=C1NC=C1C2=C(C)C=CC=C2NC1=O GMBWVUQXXBMVSA-UHFFFAOYSA-N 0.000 description 1
- PVLWGGUWOKKNRX-UHFFFAOYSA-N 3-[[4-[methyl(pyridin-3-ylmethyl)amino]anilino]methylidene]-1h-indol-2-one Chemical compound C=1C=C(NC=C2C3=CC=CC=C3NC2=O)C=CC=1N(C)CC1=CC=CN=C1 PVLWGGUWOKKNRX-UHFFFAOYSA-N 0.000 description 1
- ZZTBKRFJDFNWIY-UHFFFAOYSA-N 3-[[4-methoxy-3-(trifluoromethyl)anilino]methylidene]-4-methyl-1h-indol-2-one Chemical compound C1=C(C(F)(F)F)C(OC)=CC=C1NC=C1C2=C(C)C=CC=C2NC1=O ZZTBKRFJDFNWIY-UHFFFAOYSA-N 0.000 description 1
- OSYNFTNOUNEUHG-UHFFFAOYSA-N 3-[[n-chloro-2-(trifluoromethyl)anilino]methylidene]-1h-indol-2-one Chemical compound FC(F)(F)C1=CC=CC=C1N(Cl)C=C1C2=CC=CC=C2NC1=O OSYNFTNOUNEUHG-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- DHYHYLGCQVVLOQ-UHFFFAOYSA-N 3-bromoaniline Chemical group NC1=CC=CC(Br)=C1 DHYHYLGCQVVLOQ-UHFFFAOYSA-N 0.000 description 1
- LENYOXXELREKGZ-UHFFFAOYSA-N 3-fluoropyrrolidine;hydron;chloride Chemical compound Cl.FC1CCNC1 LENYOXXELREKGZ-UHFFFAOYSA-N 0.000 description 1
- KDHWOCLBMVSZPG-UHFFFAOYSA-N 3-imidazol-1-ylpropan-1-amine Chemical compound NCCCN1C=CN=C1 KDHWOCLBMVSZPG-UHFFFAOYSA-N 0.000 description 1
- PLRXAFVBCHEMGD-UHFFFAOYSA-N 3-piperidin-1-ylpropan-1-ol Chemical compound OCCCN1CCCCC1 PLRXAFVBCHEMGD-UHFFFAOYSA-N 0.000 description 1
- XKTYXVDYIKIYJP-UHFFFAOYSA-N 3h-dioxole Chemical compound C1OOC=C1 XKTYXVDYIKIYJP-UHFFFAOYSA-N 0.000 description 1
- MOZNZNKHRXRLLF-UHFFFAOYSA-N 4-(4-methylpiperazin-1-yl)aniline Chemical compound C1CN(C)CCN1C1=CC=C(N)C=C1 MOZNZNKHRXRLLF-UHFFFAOYSA-N 0.000 description 1
- DRYFDUUAYSVNSN-UHFFFAOYSA-N 4-(piperidin-1-ylmethyl)aniline Chemical compound C1=CC(N)=CC=C1CN1CCCCC1 DRYFDUUAYSVNSN-UHFFFAOYSA-N 0.000 description 1
- GHHQEFHFJVAIQD-UHFFFAOYSA-N 4-[(1-methylpiperidin-3-yl)methoxy]aniline Chemical compound C1N(C)CCCC1COC1=CC=C(N)C=C1 GHHQEFHFJVAIQD-UHFFFAOYSA-N 0.000 description 1
- HYRUKAFUGSKHGD-UHFFFAOYSA-N 4-[(1-methylpiperidin-3-yl)methoxy]aniline;hydrochloride Chemical compound Cl.C1N(C)CCCC1COC1=CC=C(N)C=C1 HYRUKAFUGSKHGD-UHFFFAOYSA-N 0.000 description 1
- IFIKYNZPPBYWIE-UHFFFAOYSA-N 4-fluoro-3-[(4-thiomorpholin-4-ylanilino)methylidene]-1h-indol-2-one Chemical compound C1=2C(F)=CC=CC=2NC(=O)C1=CNC(C=C1)=CC=C1N1CCSCC1 IFIKYNZPPBYWIE-UHFFFAOYSA-N 0.000 description 1
- UHPIJLSPPDLENM-UHFFFAOYSA-N 4-fluoro-3-[[3-fluoro-4-(2-hydroxyethylamino)anilino]methylidene]-1h-indol-2-one Chemical compound C1=C(F)C(NCCO)=CC=C1NC=C1C2=C(F)C=CC=C2NC1=O UHPIJLSPPDLENM-UHFFFAOYSA-N 0.000 description 1
- KHTWOYAORWYVHP-UHFFFAOYSA-N 4-fluoro-3-[[3-fluoro-4-(oxan-4-ylmethylamino)anilino]methylidene]-1h-indol-2-one Chemical compound C1=2C(F)=CC=CC=2NC(=O)C1=CNC(C=C1F)=CC=C1NCC1CCOCC1 KHTWOYAORWYVHP-UHFFFAOYSA-N 0.000 description 1
- HRCDLBRSIDTCAD-UHFFFAOYSA-N 4-fluoro-3-[[3-fluoro-4-[2-methoxyethyl(methyl)amino]anilino]methylidene]-1h-indol-2-one Chemical compound C1=C(F)C(N(C)CCOC)=CC=C1NC=C1C2=C(F)C=CC=C2NC1=O HRCDLBRSIDTCAD-UHFFFAOYSA-N 0.000 description 1
- VSSIJZOPVQCYFW-UHFFFAOYSA-N 4-fluoro-3-[[3-fluoro-4-[3-(2-methylpiperidin-1-yl)propylamino]anilino]methylidene]-1h-indol-2-one Chemical compound CC1CCCCN1CCCNC(C(=C1)F)=CC=C1NC=C1C2=C(F)C=CC=C2NC1=O VSSIJZOPVQCYFW-UHFFFAOYSA-N 0.000 description 1
- UKBHXTGOHPMBRO-UHFFFAOYSA-N 4-fluoro-3-[[3-methyl-4-(4-methylpiperidin-1-yl)anilino]methylidene]-1h-indol-2-one Chemical compound C1CC(C)CCN1C(C(=C1)C)=CC=C1NC=C1C2=C(F)C=CC=C2NC1=O UKBHXTGOHPMBRO-UHFFFAOYSA-N 0.000 description 1
- HFXYHTOSXLZZHG-UHFFFAOYSA-N 4-fluoro-3-[[3-methyl-4-[3-(2-methylpiperidin-1-yl)propylamino]anilino]methylidene]-1h-indol-2-one Chemical compound CC1CCCCN1CCCNC(C(=C1)C)=CC=C1NC=C1C2=C(F)C=CC=C2NC1=O HFXYHTOSXLZZHG-UHFFFAOYSA-N 0.000 description 1
- LBVVXQVULSOFBW-UHFFFAOYSA-N 4-fluoro-3-[[4-(1-methoxybutan-2-ylamino)-3-methylanilino]methylidene]-1h-indol-2-one Chemical compound C1=C(C)C(NC(COC)CC)=CC=C1NC=C1C2=C(F)C=CC=C2NC1=O LBVVXQVULSOFBW-UHFFFAOYSA-N 0.000 description 1
- CQWGVVQWNAPRLN-UHFFFAOYSA-N 4-fluoro-3-[[4-(4-methyl-1,4-diazepan-1-yl)anilino]methylidene]-1h-indol-2-one Chemical compound C1CN(C)CCCN1C(C=C1)=CC=C1NC=C1C2=C(F)C=CC=C2NC1=O CQWGVVQWNAPRLN-UHFFFAOYSA-N 0.000 description 1
- USRZZPHRQZGXFH-UHFFFAOYSA-N 4-methyl-1,3-dihydroindol-2-one Chemical group CC1=CC=CC2=C1CC(=O)N2 USRZZPHRQZGXFH-UHFFFAOYSA-N 0.000 description 1
- QYBDRNQHBZSOFP-UHFFFAOYSA-N 4-methyl-3-[[3-methyl-4-(2-morpholin-4-ylethylamino)anilino]methylidene]-1h-indol-2-one Chemical compound C1=2C(C)=CC=CC=2NC(=O)C1=CNC(C=C1C)=CC=C1NCCN1CCOCC1 QYBDRNQHBZSOFP-UHFFFAOYSA-N 0.000 description 1
- YIHFSUFPCXWTOP-UHFFFAOYSA-N 4-methyl-3-[[3-methyl-4-(oxan-4-ylmethylamino)anilino]methylidene]-1h-indol-2-one Chemical compound C1=2C(C)=CC=CC=2NC(=O)C1=CNC(C=C1C)=CC=C1NCC1CCOCC1 YIHFSUFPCXWTOP-UHFFFAOYSA-N 0.000 description 1
- FONMBASZACUQTB-UHFFFAOYSA-N 4-methyl-3-[[4-(2-piperidin-1-ylethoxy)anilino]methylidene]-1h-indol-2-one Chemical compound C1=2C(C)=CC=CC=2NC(=O)C1=CNC(C=C1)=CC=C1OCCN1CCCCC1 FONMBASZACUQTB-UHFFFAOYSA-N 0.000 description 1
- DFUUSWYLFYYCKM-UHFFFAOYSA-N 4-methyl-3-[[4-(4-piperidin-1-ylbutyl)anilino]methylidene]-1h-indol-2-one Chemical compound C1=2C(C)=CC=CC=2NC(=O)C1=CNC(C=C1)=CC=C1CCCCN1CCCCC1 DFUUSWYLFYYCKM-UHFFFAOYSA-N 0.000 description 1
- WFKKGJJWPBWCSF-UHFFFAOYSA-N 4-methyl-3-[[4-(morpholin-4-ylmethyl)anilino]methylidene]-1h-indol-2-one Chemical compound C1=2C(C)=CC=CC=2NC(=O)C1=CNC(C=C1)=CC=C1CN1CCOCC1 WFKKGJJWPBWCSF-UHFFFAOYSA-N 0.000 description 1
- OZTJWFOJISVWJP-UHFFFAOYSA-N 4-methyl-3-[[4-[3-(4-methylpiperazin-1-yl)propylamino]anilino]methylidene]-1h-indol-2-one Chemical compound C1CN(C)CCN1CCCNC(C=C1)=CC=C1NC=C1C2=C(C)C=CC=C2NC1=O OZTJWFOJISVWJP-UHFFFAOYSA-N 0.000 description 1
- PHNDZBFLOPIMSM-UHFFFAOYSA-N 4-morpholin-4-ylaniline Chemical compound C1=CC(N)=CC=C1N1CCOCC1 PHNDZBFLOPIMSM-UHFFFAOYSA-N 0.000 description 1
- YRISKTNAYHHICR-UHFFFAOYSA-N 4-piperidin-1-ylbutan-1-ol Chemical compound OCCCCN1CCCCC1 YRISKTNAYHHICR-UHFFFAOYSA-N 0.000 description 1
- CVICEEPAFUYBJG-UHFFFAOYSA-N 5-chloro-2,2-difluoro-1,3-benzodioxole Chemical group C1=C(Cl)C=C2OC(F)(F)OC2=C1 CVICEEPAFUYBJG-UHFFFAOYSA-N 0.000 description 1
- PGRKFGWTTKIGKS-UHFFFAOYSA-N 5-chloro-3-[(4-ethylanilino)methylidene]-1h-indol-2-one Chemical compound C1=CC(CC)=CC=C1NC=C1C2=CC(Cl)=CC=C2NC1=O PGRKFGWTTKIGKS-UHFFFAOYSA-N 0.000 description 1
- OIRHKAKKEYGXOF-UHFFFAOYSA-N 5-chloro-3-[(4-methylsulfanylanilino)methylidene]-1h-indol-2-one Chemical compound C1=CC(SC)=CC=C1NC=C1C2=CC(Cl)=CC=C2NC1=O OIRHKAKKEYGXOF-UHFFFAOYSA-N 0.000 description 1
- HOFYRFVPLSJZPC-UHFFFAOYSA-N 5-chloro-3-[[4-(piperidin-1-ylmethyl)anilino]methylidene]-1h-indol-2-one Chemical compound C12=CC(Cl)=CC=C2NC(=O)C1=CNC(C=C1)=CC=C1CN1CCCCC1 HOFYRFVPLSJZPC-UHFFFAOYSA-N 0.000 description 1
- WGTYWBFIXLUQAI-UHFFFAOYSA-N 5-fluoro-2-hydroxy-1H-indole-3-carbaldehyde Chemical compound Oc1[nH]c2ccc(F)cc2c1C=O WGTYWBFIXLUQAI-UHFFFAOYSA-N 0.000 description 1
- QBZXUNIBBIATOY-UHFFFAOYSA-N 5-fluoro-3-[[3-fluoro-4-(2-hydroxyethylamino)anilino]methylidene]-1h-indol-2-one Chemical compound C1=C(F)C(NCCO)=CC=C1NC=C1C2=CC(F)=CC=C2NC1=O QBZXUNIBBIATOY-UHFFFAOYSA-N 0.000 description 1
- LMZBEUCQGQOZQG-UHFFFAOYSA-N 5-fluoro-3-[[3-fluoro-4-(2-methoxyethylamino)anilino]methylidene]-1h-indol-2-one Chemical compound C1=C(F)C(NCCOC)=CC=C1NC=C1C2=CC(F)=CC=C2NC1=O LMZBEUCQGQOZQG-UHFFFAOYSA-N 0.000 description 1
- NFWYOJSZJRTIKF-UHFFFAOYSA-N 5-fluoro-3-[[3-fluoro-4-[(5-methylpyrazin-2-yl)methylamino]anilino]methylidene]-1h-indol-2-one Chemical compound C1=NC(C)=CN=C1CNC(C(=C1)F)=CC=C1NC=C1C2=CC(F)=CC=C2NC1=O NFWYOJSZJRTIKF-UHFFFAOYSA-N 0.000 description 1
- PYYDKGYXLYRSOT-UHFFFAOYSA-N 5-fluoro-3-[[3-fluoro-4-[2-methoxyethyl(propyl)amino]anilino]methylidene]-1h-indol-2-one Chemical compound C1=C(F)C(N(CCOC)CCC)=CC=C1NC=C1C2=CC(F)=CC=C2NC1=O PYYDKGYXLYRSOT-UHFFFAOYSA-N 0.000 description 1
- NWFKVIDIFVTAQD-UHFFFAOYSA-N 5-fluoro-3-[[4-(3-oxopiperazin-1-yl)anilino]methylidene]-1h-indol-2-one Chemical compound C12=CC(F)=CC=C2NC(=O)C1=CNC(C=C1)=CC=C1N1CCNC(=O)C1 NWFKVIDIFVTAQD-UHFFFAOYSA-N 0.000 description 1
- MTXBLPZGBQUAEX-UHFFFAOYSA-N 5-fluoro-3-[[4-(pyridin-2-ylmethylamino)anilino]methylidene]-1h-indol-2-one;5-fluoro-3-[[4-(pyridin-3-ylmethylamino)anilino]methylidene]-1h-indol-2-one Chemical compound C12=CC(F)=CC=C2NC(=O)C1=CNC(C=C1)=CC=C1NCC1=CC=CN=C1.C12=CC(F)=CC=C2NC(=O)C1=CNC(C=C1)=CC=C1NCC1=CC=CC=N1 MTXBLPZGBQUAEX-UHFFFAOYSA-N 0.000 description 1
- KCGZATCJOTZIAL-UHFFFAOYSA-N 5-fluoro-3-[[4-[2-(3-fluoropyrrolidin-1-yl)ethoxy]anilino]methylidene]-1h-indol-2-one Chemical compound C1C(F)CCN1CCOC(C=C1)=CC=C1NC=C1C2=CC(F)=CC=C2NC1=O KCGZATCJOTZIAL-UHFFFAOYSA-N 0.000 description 1
- ATAISBCUMMRTSJ-UHFFFAOYSA-N 5-fluoro-3-[[4-[2-methoxyethyl(methyl)amino]anilino]methylidene]-1h-indol-2-one Chemical compound C1=CC(N(C)CCOC)=CC=C1NC=C1C2=CC(F)=CC=C2NC1=O ATAISBCUMMRTSJ-UHFFFAOYSA-N 0.000 description 1
- PKQNTFAOZIVXCE-UHFFFAOYSA-N 6-fluoro-1,3-dihydroindol-2-one Chemical group FC1=CC=C2CC(=O)NC2=C1 PKQNTFAOZIVXCE-UHFFFAOYSA-N 0.000 description 1
- VLLSZFRNMRIVBR-UHFFFAOYSA-N 6-fluoro-3-[(3-fluoro-4-morpholin-4-ylanilino)methylidene]-1h-indol-2-one Chemical compound O=C1NC2=CC(F)=CC=C2C1=CNC(C=C1F)=CC=C1N1CCOCC1 VLLSZFRNMRIVBR-UHFFFAOYSA-N 0.000 description 1
- CUAWTQWXAYDPQC-UHFFFAOYSA-N 6-fluoro-3-[[3-fluoro-4-(1-methoxybutan-2-ylamino)anilino]methylidene]-1h-indol-2-one Chemical compound C1=C(F)C(NC(COC)CC)=CC=C1NC=C1C2=CC=C(F)C=C2NC1=O CUAWTQWXAYDPQC-UHFFFAOYSA-N 0.000 description 1
- FWMCKPADLJPXRL-UHFFFAOYSA-N 6-fluoro-3-[[3-fluoro-4-[(1,2,2,6,6-pentamethylpiperidin-4-yl)amino]anilino]methylidene]-1h-indol-2-one Chemical compound C1C(C)(C)N(C)C(C)(C)CC1NC(C(=C1)F)=CC=C1NC=C1C2=CC=C(F)C=C2NC1=O FWMCKPADLJPXRL-UHFFFAOYSA-N 0.000 description 1
- WNAXMAMRBBNPMR-UHFFFAOYSA-N 6-fluoro-3-[[4-(1-methoxypropan-2-ylamino)-3-(trifluoromethyl)anilino]methylidene]-1h-indol-2-one Chemical compound C1=C(C(F)(F)F)C(NC(C)COC)=CC=C1NC=C1C2=CC=C(F)C=C2NC1=O WNAXMAMRBBNPMR-UHFFFAOYSA-N 0.000 description 1
- GSRJARIWHBZJCC-UHFFFAOYSA-N 6-fluoro-3-[[4-(2-pyrrolidin-1-ylethoxy)anilino]methylidene]-1h-indol-2-one Chemical compound O=C1NC2=CC(F)=CC=C2C1=CNC(C=C1)=CC=C1OCCN1CCCC1 GSRJARIWHBZJCC-UHFFFAOYSA-N 0.000 description 1
- UYQGGRVCFRSFOS-UHFFFAOYSA-N 6-fluoro-3-[[4-(morpholin-4-ylmethyl)anilino]methylidene]-1h-indol-2-one Chemical compound O=C1NC2=CC(F)=CC=C2C1=CNC(C=C1)=CC=C1CN1CCOCC1 UYQGGRVCFRSFOS-UHFFFAOYSA-N 0.000 description 1
- APNCLYRLCSHOBJ-UHFFFAOYSA-N 6-fluoro-3-[[4-[2-(3-fluoropyrrolidin-1-yl)ethoxy]anilino]methylidene]-1h-indol-2-one Chemical compound C1C(F)CCN1CCOC(C=C1)=CC=C1NC=C1C2=CC=C(F)C=C2NC1=O APNCLYRLCSHOBJ-UHFFFAOYSA-N 0.000 description 1
- GGFPWCUPKZJYSE-UHFFFAOYSA-N 6-fluoro-3-[[4-[2-methoxyethyl(methyl)amino]anilino]methylidene]-1h-indol-2-one Chemical compound C1=CC(N(C)CCOC)=CC=C1NC=C1C2=CC=C(F)C=C2NC1=O GGFPWCUPKZJYSE-UHFFFAOYSA-N 0.000 description 1
- QXBVXPUAVHFWRS-UHFFFAOYSA-N 6-fluoro-3-[[4-[2-methoxyethyl(propyl)amino]anilino]methylidene]-1h-indol-2-one Chemical compound C1=CC(N(CCOC)CCC)=CC=C1NC=C1C2=CC=C(F)C=C2NC1=O QXBVXPUAVHFWRS-UHFFFAOYSA-N 0.000 description 1
- JAXHTPVITMGZIQ-UHFFFAOYSA-N 6-fluoro-3-[[4-[3-(4-methylpiperazin-1-yl)propylamino]anilino]methylidene]-1h-indol-2-one Chemical compound C1CN(C)CCN1CCCNC(C=C1)=CC=C1NC=C1C2=CC=C(F)C=C2NC1=O JAXHTPVITMGZIQ-UHFFFAOYSA-N 0.000 description 1
- 102000007299 Amphiregulin Human genes 0.000 description 1
- 108010033760 Amphiregulin Proteins 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 206010003571 Astrocytoma Diseases 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- OGBVRMYSNSKIEF-UHFFFAOYSA-N Benzylphosphonic acid Chemical class OP(O)(=O)CC1=CC=CC=C1 OGBVRMYSNSKIEF-UHFFFAOYSA-N 0.000 description 1
- 102000056058 Betacellulin Human genes 0.000 description 1
- 101800001382 Betacellulin Proteins 0.000 description 1
- 206010005949 Bone cancer Diseases 0.000 description 1
- 208000018084 Bone neoplasm Diseases 0.000 description 1
- WNPNGMJZEVNKKN-UHFFFAOYSA-N BrC1=CC=C(C=C1)NCC1C(NC2=CC=CC=C12)=O.BrC=1C=C(C=CC1)NC=C1C(NC2=CC=CC=C12)=O.C1(=CC=CC=C1)NC=C1C(NC2=CC=CC=C12)=O Chemical compound BrC1=CC=C(C=C1)NCC1C(NC2=CC=CC=C12)=O.BrC=1C=C(C=CC1)NC=C1C(NC2=CC=CC=C12)=O.C1(=CC=CC=C1)NC=C1C(NC2=CC=CC=C12)=O WNPNGMJZEVNKKN-UHFFFAOYSA-N 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- QHWHVEHVXFWQEI-UHFFFAOYSA-N C12=CC(F)=CC=C2NC(=O)C1=CNC(C=C1)=CC=C1N1CCN(C=O)CC1 Chemical compound C12=CC(F)=CC=C2NC(=O)C1=CNC(C=C1)=CC=C1N1CCN(C=O)CC1 QHWHVEHVXFWQEI-UHFFFAOYSA-N 0.000 description 1
- FAZGFVDGIRTETR-UHFFFAOYSA-N C1=2C(F)=CC=CC=2NC(=O)C1=CNC(C=C1F)=CC=C1N1CCN(C=O)CC1 Chemical compound C1=2C(F)=CC=CC=2NC(=O)C1=CNC(C=C1F)=CC=C1N1CCN(C=O)CC1 FAZGFVDGIRTETR-UHFFFAOYSA-N 0.000 description 1
- LXIIODFBGTZYIS-UHFFFAOYSA-N C1=CC(OC(F)F)=CC=C1NC=C1C2=CC(Cl)=CC=C2NC1=O Chemical compound C1=CC(OC(F)F)=CC=C1NC=C1C2=CC(Cl)=CC=C2NC1=O LXIIODFBGTZYIS-UHFFFAOYSA-N 0.000 description 1
- COXVTLYNGOIATD-HVMBLDELSA-N CC1=C(C=CC(=C1)C1=CC(C)=C(C=C1)\N=N\C1=C(O)C2=C(N)C(=CC(=C2C=C1)S(O)(=O)=O)S(O)(=O)=O)\N=N\C1=CC=C2C(=CC(=C(N)C2=C1O)S(O)(=O)=O)S(O)(=O)=O Chemical compound CC1=C(C=CC(=C1)C1=CC(C)=C(C=C1)\N=N\C1=C(O)C2=C(N)C(=CC(=C2C=C1)S(O)(=O)=O)S(O)(=O)=O)\N=N\C1=CC=C2C(=CC(=C(N)C2=C1O)S(O)(=O)=O)S(O)(=O)=O COXVTLYNGOIATD-HVMBLDELSA-N 0.000 description 1
- JIFLPTUSBGDLBA-UHFFFAOYSA-N CC1=CC(NC=C2C3=CC(F)=CC=C3NC2=O)=CC=C1N1CCN(C=O)CC1 Chemical compound CC1=CC(NC=C2C3=CC(F)=CC=C3NC2=O)=CC=C1N1CCN(C=O)CC1 JIFLPTUSBGDLBA-UHFFFAOYSA-N 0.000 description 1
- OAJLFPDXCLVCQC-UHFFFAOYSA-N CC1=CC(NC=C2C3=CC=C(F)C=C3NC2=O)=CC=C1N1CCN(C=O)CC1 Chemical compound CC1=CC(NC=C2C3=CC=C(F)C=C3NC2=O)=CC=C1N1CCN(C=O)CC1 OAJLFPDXCLVCQC-UHFFFAOYSA-N 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- ZEOWTGPWHLSLOG-UHFFFAOYSA-N Cc1ccc(cc1-c1ccc2c(n[nH]c2c1)-c1cnn(c1)C1CC1)C(=O)Nc1cccc(c1)C(F)(F)F Chemical compound Cc1ccc(cc1-c1ccc2c(n[nH]c2c1)-c1cnn(c1)C1CC1)C(=O)Nc1cccc(c1)C(F)(F)F ZEOWTGPWHLSLOG-UHFFFAOYSA-N 0.000 description 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 101000827763 Drosophila melanogaster Fibroblast growth factor receptor homolog 1 Proteins 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 108091008794 FGF receptors Proteins 0.000 description 1
- 102100023593 Fibroblast growth factor receptor 1 Human genes 0.000 description 1
- 101710182386 Fibroblast growth factor receptor 1 Proteins 0.000 description 1
- 102100023600 Fibroblast growth factor receptor 2 Human genes 0.000 description 1
- 101710182389 Fibroblast growth factor receptor 2 Proteins 0.000 description 1
- 102100027842 Fibroblast growth factor receptor 3 Human genes 0.000 description 1
- 101710182396 Fibroblast growth factor receptor 3 Proteins 0.000 description 1
- 102100027844 Fibroblast growth factor receptor 4 Human genes 0.000 description 1
- 102100037362 Fibronectin Human genes 0.000 description 1
- 108010067306 Fibronectins Proteins 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- OUVXYXNWSVIOSJ-UHFFFAOYSA-N Fluo-4 Chemical compound CC1=CC=C(N(CC(O)=O)CC(O)=O)C(OCCOC=2C(=CC=C(C=2)C2=C3C=C(F)C(=O)C=C3OC3=CC(O)=C(F)C=C32)N(CC(O)=O)CC(O)=O)=C1 OUVXYXNWSVIOSJ-UHFFFAOYSA-N 0.000 description 1
- YSWHPLCDIMUKFE-QWRGUYRKSA-N Glu-Tyr Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 YSWHPLCDIMUKFE-QWRGUYRKSA-N 0.000 description 1
- 102000018710 Heparin-binding EGF-like Growth Factor Human genes 0.000 description 1
- 101800001649 Heparin-binding EGF-like growth factor Proteins 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 101000917134 Homo sapiens Fibroblast growth factor receptor 4 Proteins 0.000 description 1
- 101001005128 Homo sapiens LIM domain kinase 1 Proteins 0.000 description 1
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 1
- 101000808011 Homo sapiens Vascular endothelial growth factor A Proteins 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 1
- 102100026023 LIM domain kinase 1 Human genes 0.000 description 1
- 101100268066 Mus musculus Zap70 gene Proteins 0.000 description 1
- 208000007727 Muscle Tissue Neoplasms Diseases 0.000 description 1
- FEYNFHSRETUBEM-UHFFFAOYSA-N N-[3-(1,1-difluoroethyl)phenyl]-1-(4-methoxyphenyl)-3-methyl-5-oxo-4H-pyrazole-4-carboxamide Chemical compound COc1ccc(cc1)N1N=C(C)C(C(=O)Nc2cccc(c2)C(C)(F)F)C1=O FEYNFHSRETUBEM-UHFFFAOYSA-N 0.000 description 1
- 102400000058 Neuregulin-1 Human genes 0.000 description 1
- 108090000556 Neuregulin-1 Proteins 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- MHABMANUFPZXEB-UHFFFAOYSA-N O-demethyl-aloesaponarin I Natural products O=C1C2=CC=CC(O)=C2C(=O)C2=C1C=C(O)C(C(O)=O)=C2C MHABMANUFPZXEB-UHFFFAOYSA-N 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- ABLZXFCXXLZCGV-UHFFFAOYSA-N Phosphorous acid Chemical compound OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 description 1
- 102000016971 Proto-Oncogene Proteins c-kit Human genes 0.000 description 1
- 108010014608 Proto-Oncogene Proteins c-kit Proteins 0.000 description 1
- 101000852966 Rattus norvegicus Interleukin-1 receptor-like 1 Proteins 0.000 description 1
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 1
- 101710100969 Receptor tyrosine-protein kinase erbB-3 Proteins 0.000 description 1
- 102100029986 Receptor tyrosine-protein kinase erbB-3 Human genes 0.000 description 1
- 102100029981 Receptor tyrosine-protein kinase erbB-4 Human genes 0.000 description 1
- 101710100963 Receptor tyrosine-protein kinase erbB-4 Proteins 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 229910010061 TiC13 Inorganic materials 0.000 description 1
- BGDKAVGWHJFAGW-UHFFFAOYSA-N Tropicamide Chemical compound C=1C=CC=CC=1C(CO)C(=O)N(CC)CC1=CC=NC=C1 BGDKAVGWHJFAGW-UHFFFAOYSA-N 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 108091008605 VEGF receptors Proteins 0.000 description 1
- 102000009484 Vascular Endothelial Growth Factor Receptors Human genes 0.000 description 1
- 230000001594 aberrant effect Effects 0.000 description 1
- 150000001338 aliphatic hydrocarbons Chemical class 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 150000001448 anilines Chemical class 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 208000021592 benign granular cell tumor Diseases 0.000 description 1
- 125000005841 biaryl group Chemical group 0.000 description 1
- 125000002619 bicyclic group Chemical group 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 125000006367 bivalent amino carbonyl group Chemical group [H]N([*:1])C([*:2])=O 0.000 description 1
- 239000001045 blue dye Substances 0.000 description 1
- 238000011685 brown norway rat Methods 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 125000002837 carbocyclic group Chemical group 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 239000003610 charcoal Substances 0.000 description 1
- DGLFSNZWRYADFC-UHFFFAOYSA-N chembl2334586 Chemical compound C1CCC2=CN=C(N)N=C2C2=C1NC1=CC=C(C#CC(C)(O)C)C=C12 DGLFSNZWRYADFC-UHFFFAOYSA-N 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000001427 coherent effect Effects 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 125000004663 dialkyl amino group Chemical group 0.000 description 1
- BEPAFCGSDWSTEL-UHFFFAOYSA-N dimethyl malonate Chemical compound COC(=O)CC(=O)OC BEPAFCGSDWSTEL-UHFFFAOYSA-N 0.000 description 1
- 208000037765 diseases and disorders Diseases 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 description 1
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 description 1
- 230000008472 epithelial growth Effects 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- 229960003699 evans blue Drugs 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 108091071773 flk family Proteins 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 238000011597 hartley guinea pig Methods 0.000 description 1
- 201000011066 hemangioma Diseases 0.000 description 1
- 201000005787 hematologic cancer Diseases 0.000 description 1
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 239000012456 homogeneous solution Substances 0.000 description 1
- 102000058223 human VEGFA Human genes 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical group 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 230000000521 hyperimmunizing effect Effects 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 238000010191 image analysis Methods 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 150000002460 imidazoles Chemical class 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 1
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- JMMWKPVZQRWMSS-UHFFFAOYSA-N isopropanol acetate Natural products CC(C)OC(C)=O JMMWKPVZQRWMSS-UHFFFAOYSA-N 0.000 description 1
- 229960003299 ketamine Drugs 0.000 description 1
- 238000000021 kinase assay Methods 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 206010027191 meningioma Diseases 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- OSELWTGCULLKDP-UHFFFAOYSA-N methyl 1-[2-fluoro-4-[(5-fluoro-2-oxo-1h-indol-3-ylidene)methylamino]phenyl]piperidine-4-carboxylate Chemical compound C1CC(C(=O)OC)CCN1C(C(=C1)F)=CC=C1NC=C1C2=CC(F)=CC=C2NC1=O OSELWTGCULLKDP-UHFFFAOYSA-N 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 125000002950 monocyclic group Chemical group 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 201000004130 myoblastoma Diseases 0.000 description 1
- NBBUFLXUBLYNPY-UHFFFAOYSA-N n,n-bis(2-hydroxyethyl)-3-[(4-methyl-2-oxo-1h-indol-3-ylidene)methylamino]benzenesulfonamide Chemical compound C1=2C(C)=CC=CC=2NC(=O)C1=CNC1=CC=CC(S(=O)(=O)N(CCO)CCO)=C1 NBBUFLXUBLYNPY-UHFFFAOYSA-N 0.000 description 1
- ZLZZAXUKBHFTHA-UHFFFAOYSA-N n,n-diethyl-2-(4-nitrophenoxy)ethanamine Chemical compound CCN(CC)CCOC1=CC=C([N+]([O-])=O)C=C1 ZLZZAXUKBHFTHA-UHFFFAOYSA-N 0.000 description 1
- GDLYTJHSJZNSPZ-UHFFFAOYSA-N n,n-diethyl-3-(2-fluoro-4-nitrophenoxy)propan-1-amine Chemical compound CCN(CC)CCCOC1=CC=C([N+]([O-])=O)C=C1F GDLYTJHSJZNSPZ-UHFFFAOYSA-N 0.000 description 1
- FMASTMURQSHELY-UHFFFAOYSA-N n-(4-fluoro-2-methylphenyl)-3-methyl-n-[(2-methyl-1h-indol-4-yl)methyl]pyridine-4-carboxamide Chemical compound C1=CC=C2NC(C)=CC2=C1CN(C=1C(=CC(F)=CC=1)C)C(=O)C1=CC=NC=C1C FMASTMURQSHELY-UHFFFAOYSA-N 0.000 description 1
- SPAQHUHOFHUIEV-UHFFFAOYSA-N n-[3-(4-methylpiperazin-1-yl)propyl]-4-nitroaniline Chemical compound C1CN(C)CCN1CCCNC1=CC=C([N+]([O-])=O)C=C1 SPAQHUHOFHUIEV-UHFFFAOYSA-N 0.000 description 1
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 description 1
- 230000009826 neoplastic cell growth Effects 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen(.) Chemical compound [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 125000006501 nitrophenyl group Chemical group 0.000 description 1
- 210000003733 optic disk Anatomy 0.000 description 1
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- WEYVCQFUGFRXOM-UHFFFAOYSA-N perazine Chemical compound C1CN(C)CCN1CCCN1C2=CC=CC=C2SC2=CC=CC=C21 WEYVCQFUGFRXOM-UHFFFAOYSA-N 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000007981 phosphate-citrate buffer Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 1
- 238000004237 preparative chromatography Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 210000001747 pupil Anatomy 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 125000002294 quinazolinyl group Chemical class N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 210000001210 retinal vessel Anatomy 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 150000003346 selenoethers Chemical class 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 229910000104 sodium hydride Inorganic materials 0.000 description 1
- QGMRQYFBGABWDR-UHFFFAOYSA-N sodium;5-ethyl-5-pentan-2-yl-1,3-diazinane-2,4,6-trione Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)NC1=O QGMRQYFBGABWDR-UHFFFAOYSA-N 0.000 description 1
- 239000011343 solid material Substances 0.000 description 1
- 125000005504 styryl group Chemical group 0.000 description 1
- 229940124530 sulfonamide Drugs 0.000 description 1
- 150000003456 sulfonamides Chemical class 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- KYHHOMOFYMXMSZ-UHFFFAOYSA-N tert-butyl 3-[4-[(4-fluoro-2-oxo-1h-indol-3-ylidene)methylamino]-2-methylanilino]pyrrolidine-1-carboxylate Chemical compound CC1=CC(NC=C2C3=C(F)C=CC=C3NC2=O)=CC=C1NC1CCN(C(=O)OC(C)(C)C)C1 KYHHOMOFYMXMSZ-UHFFFAOYSA-N 0.000 description 1
- LPQZERIRKRYGGM-UHFFFAOYSA-N tert-butyl pyrrolidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCCC1 LPQZERIRKRYGGM-UHFFFAOYSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 150000003573 thiols Chemical class 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 102000027257 transmembrane receptors Human genes 0.000 description 1
- 108091008578 transmembrane receptors Proteins 0.000 description 1
- 125000004953 trihalomethyl group Chemical group 0.000 description 1
- 229960004791 tropicamide Drugs 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 210000003606 umbilical vein Anatomy 0.000 description 1
- 241000701447 unidentified baculovirus Species 0.000 description 1
- AQLJVWUFPCUVLO-UHFFFAOYSA-N urea hydrogen peroxide Chemical compound OO.NC(N)=O AQLJVWUFPCUVLO-UHFFFAOYSA-N 0.000 description 1
- BPICBUSOMSTKRF-UHFFFAOYSA-N xylazine Chemical compound CC1=CC=CC(C)=C1NC1=NCCCS1 BPICBUSOMSTKRF-UHFFFAOYSA-N 0.000 description 1
- 229960001600 xylazine Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
- C07D295/084—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
- C07D295/088—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/32—Oxygen atoms
- C07D209/34—Oxygen atoms in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
- C07D295/135—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Rheumatology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Dermatology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Pain & Pain Management (AREA)
- Surgery (AREA)
- Endocrinology (AREA)
- Hospice & Palliative Care (AREA)
- Transplantation (AREA)
- Heart & Thoracic Surgery (AREA)
- Psychiatry (AREA)
- Ophthalmology & Optometry (AREA)
- Cardiology (AREA)
- Pulmonology (AREA)
- Gastroenterology & Hepatology (AREA)
- Vascular Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US32581501P | 2001-09-27 | 2001-09-27 | |
| US32581901P | 2001-09-27 | 2001-09-27 | |
| US60/325,819 | 2001-09-27 | ||
| US60/325,815 | 2001-09-27 | ||
| PCT/US2002/030882 WO2003027102A1 (en) | 2001-09-27 | 2002-09-27 | 3-(arylamino)methylene-1, 3-dihydro-2h-indol-2-ones as kinase inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2002341881A1 AU2002341881A1 (en) | 2003-06-26 |
| AU2002341881B2 true AU2002341881B2 (en) | 2008-05-08 |
Family
ID=26985125
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2002341881A Ceased AU2002341881B2 (en) | 2001-09-27 | 2002-09-27 | 3-(arylamino)methylene-1, 3-dihydro-2h-indol-2-ones as kinase inhibitors |
Country Status (6)
| Country | Link |
|---|---|
| US (7) | US6765012B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP1430048A1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP2005508336A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2002341881B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2461812C (cg-RX-API-DMAC7.html) |
| WO (1) | WO2003027102A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (79)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1998046588A2 (en) * | 1997-04-11 | 1998-10-22 | Neorx Corporation | Compounds and therapies for the prevention of vascular and non-vascular pathologies |
| US20030153015A1 (en) * | 2000-01-20 | 2003-08-14 | Genentech, Inc. | Compositions and methods for the treatment of immune related diseases |
| KR100600550B1 (ko) | 2000-10-20 | 2006-07-13 | 에자이 가부시키가이샤 | 질소 함유 방향환 유도체 |
| AU2002341881B2 (en) * | 2001-09-27 | 2008-05-08 | Allergan, Inc. | 3-(arylamino)methylene-1, 3-dihydro-2h-indol-2-ones as kinase inhibitors |
| PE20040701A1 (es) * | 2002-07-23 | 2004-11-30 | Boehringer Ingelheim Pharma | Derivados de indolinona sustituidos en posicion 6 y su preparacion como medicamentos |
| US7169936B2 (en) | 2002-07-23 | 2007-01-30 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Indolinone derivatives substituted in the 6-position, their preparation and their use as medicaments |
| US7514468B2 (en) | 2002-07-23 | 2009-04-07 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Indolinone derivatives substituted in the 6 position, the preparation thereof and their use as pharmaceutical compositions |
| DE10233366A1 (de) * | 2002-07-23 | 2004-02-12 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | In 6-Stellung substituierte Indolinonderivate, ihre Herstellung und ihre Verwendung als Arzneimittel |
| WO2005044788A1 (ja) | 2003-11-11 | 2005-05-19 | Eisai Co., Ltd. | ウレア誘導体およびその製造方法 |
| US20050101582A1 (en) * | 2003-11-12 | 2005-05-12 | Allergan, Inc. | Compositions and methods for treating a posterior segment of an eye |
| US20070224278A1 (en) | 2003-11-12 | 2007-09-27 | Lyons Robert T | Low immunogenicity corticosteroid compositions |
| DE602005011928D1 (de) | 2004-01-20 | 2009-02-05 | Allergan Inc | Zusammensetzungen für die lokalisierte therapie des auges, vorzugsweise enthaltend triamcinolon-acetonid und hyaluronsäure |
| US7338536B2 (en) | 2004-02-27 | 2008-03-04 | L'oreal S. A. | N-alkylamino secondary para-phenylenediamine, composition for dyeing keratin fibers comprising such a para-phenylenediamine, processes using this composition and uses thereof |
| FR2866879A1 (fr) * | 2004-02-27 | 2005-09-02 | Oreal | Para-phenylenediamine secondaire n-alkylaminee, composition de teinture des fibres keratiniques contenant une telle para-phenylenediamine, procedes mettant en oeuvre cette composition et utilisations |
| KR100629713B1 (ko) * | 2004-04-10 | 2006-09-29 | (주)아모레퍼시픽 | 펜타에리스리톨 유도체와 이의 제조방법, 및 이를포함하는 액정베이스 |
| US9498457B2 (en) | 2004-04-30 | 2016-11-22 | Allergan, Inc. | Hypotensive prostamide-containing biodegradable intraocular implants and related implants |
| US7771742B2 (en) * | 2004-04-30 | 2010-08-10 | Allergan, Inc. | Sustained release intraocular implants containing tyrosine kinase inhibitors and related methods |
| US20050244458A1 (en) * | 2004-04-30 | 2005-11-03 | Allergan, Inc. | Sustained release intraocular implants and methods for treating ocular neuropathies |
| WO2005107708A1 (en) | 2004-04-30 | 2005-11-17 | Allergan, Inc. | Biodegradable intravitreal tyrosine kinase inhibitors implants |
| US8591885B2 (en) * | 2004-04-30 | 2013-11-26 | Allergan, Inc. | Carbonic anhydrase inhibitor sustained release intraocular drug delivery systems |
| US8673341B2 (en) | 2004-04-30 | 2014-03-18 | Allergan, Inc. | Intraocular pressure reduction with intracameral bimatoprost implants |
| US8147865B2 (en) | 2004-04-30 | 2012-04-03 | Allergan, Inc. | Steroid-containing sustained release intraocular implants and related methods |
| US8119154B2 (en) | 2004-04-30 | 2012-02-21 | Allergan, Inc. | Sustained release intraocular implants and related methods |
| US8455656B2 (en) | 2004-04-30 | 2013-06-04 | Allergan, Inc. | Kinase inhibitors |
| US20050244472A1 (en) * | 2004-04-30 | 2005-11-03 | Allergan, Inc. | Intraocular drug delivery systems containing excipients with reduced toxicity and related methods |
| US8425929B2 (en) | 2004-04-30 | 2013-04-23 | Allergan, Inc. | Sustained release intraocular implants and methods for preventing retinal dysfunction |
| US7993634B2 (en) | 2004-04-30 | 2011-08-09 | Allergan, Inc. | Oil-in-oil emulsified polymeric implants containing a hypotensive lipid and related methods |
| US20050244463A1 (en) | 2004-04-30 | 2005-11-03 | Allergan, Inc. | Sustained release intraocular implants and methods for treating ocular vasculopathies |
| US20070059336A1 (en) * | 2004-04-30 | 2007-03-15 | Allergan, Inc. | Anti-angiogenic sustained release intraocular implants and related methods |
| US20050244478A1 (en) * | 2004-04-30 | 2005-11-03 | Allergan, Inc. | Anti-excititoxic sustained release intraocular implants and related methods |
| US20050244461A1 (en) * | 2004-04-30 | 2005-11-03 | Allergan, Inc. | Controlled release drug delivery systems and methods for treatment of an eye |
| US7799336B2 (en) | 2004-04-30 | 2010-09-21 | Allergan, Inc. | Hypotensive lipid-containing biodegradable intraocular implants and related methods |
| US8722097B2 (en) | 2004-04-30 | 2014-05-13 | Allergan, Inc. | Oil-in-water method for making polymeric implants containing a hypotensive lipid |
| US20050244462A1 (en) * | 2004-04-30 | 2005-11-03 | Allergan, Inc. | Devices and methods for treating a mammalian eye |
| US20050244471A1 (en) * | 2004-04-30 | 2005-11-03 | Allergan, Inc. | Estradiol derivative and estratopone containing sustained release intraocular implants and related methods |
| US20050244466A1 (en) * | 2004-04-30 | 2005-11-03 | Allergan, Inc. | Photodynamic therapy in conjunction with intraocular implants |
| JP4834553B2 (ja) | 2004-09-17 | 2011-12-14 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 医薬組成物 |
| TW200640443A (en) | 2005-02-23 | 2006-12-01 | Alcon Inc | Methods for treating ocular angiogenesis, retinal edema, retinal ischemia, and diabetic retinopathy using selective RTK inhibitors |
| US7309787B2 (en) * | 2005-07-13 | 2007-12-18 | Allergan, Inc. | Kinase inhibitors |
| CA2602389A1 (en) | 2005-07-13 | 2007-01-18 | Allergan, Inc. | Kinase inhibitors |
| AU2006268174A1 (en) * | 2005-07-13 | 2007-01-18 | Allergan, Inc. | Kinase inhibitors |
| US7749530B2 (en) | 2005-07-13 | 2010-07-06 | Allergan, Inc. | Kinase inhibitors |
| US9006240B2 (en) | 2005-08-02 | 2015-04-14 | Eisai R&D Management Co., Ltd. | Method for assay on the effect of vascularization inhibitor |
| US8367664B2 (en) * | 2006-01-24 | 2013-02-05 | Allergan, Inc. | Substituted 3-(5-membered unsaturated heterocyclyl-1, 3-dihydro-indol-2-one's and derivatives thereof as kinase inhibitors |
| US7977351B2 (en) | 2006-03-22 | 2011-07-12 | Allergan, Inc. | Heteroaryl dihydroindolones as kinase inhibitors |
| RU2448708C3 (ru) | 2006-05-18 | 2017-09-28 | Эйсай Ар Энд Ди Менеджмент Ко., Лтд. | Противоопухолевое средство против рака щитовидной железы |
| WO2008022013A1 (en) * | 2006-08-11 | 2008-02-21 | Allergan, Inc. | Kinase inhibitors |
| CN101511793B (zh) | 2006-08-28 | 2011-08-03 | 卫材R&D管理有限公司 | 针对未分化型胃癌的抗肿瘤剂 |
| US8558002B2 (en) | 2006-11-16 | 2013-10-15 | Allergan, Inc. | Sulfoximines as kinase inhibitors |
| US8143410B2 (en) | 2006-11-16 | 2012-03-27 | Allergan, Inc. | Kinase inhibitors |
| US8969415B2 (en) | 2006-12-01 | 2015-03-03 | Allergan, Inc. | Intraocular drug delivery systems |
| EP2119707B1 (en) | 2007-01-29 | 2015-01-14 | Eisai R&D Management Co., Ltd. | Composition for treatment of undifferentiated-type of gastric cancer |
| US8642067B2 (en) | 2007-04-02 | 2014-02-04 | Allergen, Inc. | Methods and compositions for intraocular administration to treat ocular conditions |
| US7911053B2 (en) * | 2007-04-19 | 2011-03-22 | Marvell World Trade Ltd. | Semiconductor packaging with internal wiring bus |
| EP2170827B1 (en) * | 2007-06-21 | 2013-08-14 | Janssen Pharmaceutica, N.V. | Indolin-2-ones and aza-indolin-2-ones |
| JP5209254B2 (ja) * | 2007-08-30 | 2013-06-12 | 日本曹達株式会社 | 置換フェノキシアザビシクロオクタン誘導体の製造方法 |
| WO2009060945A1 (ja) | 2007-11-09 | 2009-05-14 | Eisai R & D Management Co., Ltd. | 血管新生阻害物質と抗腫瘍性白金錯体との併用 |
| US9340555B2 (en) | 2009-09-03 | 2016-05-17 | Allergan, Inc. | Compounds as tyrosine kinase modulators |
| US8809534B2 (en) | 2009-09-03 | 2014-08-19 | Allergan, Inc. | Compounds as tyrosine kinase modulators |
| JP5982287B2 (ja) | 2009-11-09 | 2016-08-31 | アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ | 発毛を刺激する組成物および方法 |
| AU2011270165B2 (en) | 2010-06-25 | 2015-12-24 | Eisai R&D Management Co., Ltd. | Antitumor agent using compounds having kinase inhibitory effect in combination |
| JP6021805B2 (ja) | 2011-04-18 | 2016-11-09 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 腫瘍治療剤 |
| EP3444363B1 (en) | 2011-06-03 | 2020-11-25 | Eisai R&D Management Co., Ltd. | Biomarkers for prediciting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds |
| CN103304468A (zh) * | 2012-03-13 | 2013-09-18 | 华东师范大学 | 一种氧化吲哚的一锅法串联合成方法 |
| US9642851B2 (en) | 2012-12-06 | 2017-05-09 | Kbp Biosciences Co., Ltd. | Indolinone derivative as tyrosine kinase inhibitor |
| JPWO2014098176A1 (ja) | 2012-12-21 | 2017-01-12 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | キノリン誘導体のアモルファス及びその製造方法 |
| HK1218850A1 (zh) | 2013-02-15 | 2017-03-17 | Allergan, Inc. | 持续药物递送植入物 |
| CN105264380B (zh) | 2013-05-14 | 2017-09-05 | 卫材R&D管理有限公司 | 用于预测和评价子宫内膜癌受试者对乐伐替尼化合物响应性的生物标志 |
| WO2014201587A1 (zh) * | 2013-06-20 | 2014-12-24 | 中国人民解放军军事医学科学院放射与辐射医学研究所 | 具有酪氨酸激酶抑制活性的物质、其制备方法及用途 |
| SMT202200367T1 (it) | 2014-08-28 | 2022-11-18 | Eisai R&D Man Co Ltd | Derivato di chinolina a elevata purezza e metodo per la produzione dello stesso |
| CA2976325C (en) | 2015-02-25 | 2023-07-04 | Eisai R&D Management Co., Ltd. | Method for suppressing bitterness of quinoline derivative |
| KR102662228B1 (ko) | 2015-03-04 | 2024-05-02 | 머크 샤프 앤드 돔 코포레이션 | 암을 치료하기 위한 pd-1 길항제 및 vegfr/fgfr/ret 티로신 키나제 억제제의 조합 |
| CN107801379B (zh) | 2015-06-16 | 2021-05-25 | 卫材R&D管理有限公司 | 抗癌剂 |
| AU2016309356B2 (en) | 2015-08-20 | 2021-06-24 | Eisai R&D Management Co., Ltd. | Tumor therapeutic agent |
| ES2971448T3 (es) | 2017-02-08 | 2024-06-05 | Eisai R&D Man Co Ltd | Composición farmacéutica para el tratamiento de tumores |
| CN108822017A (zh) * | 2017-04-11 | 2018-11-16 | 中国医学科学院药物研究所 | 新型吲哚酮化合物及其制法和药物用途 |
| CA3061888A1 (en) | 2017-05-16 | 2018-11-22 | Eisai R&D Management Co., Ltd. | Treatment of hepatocellular carcinoma |
| WO2020070332A1 (en) * | 2018-10-05 | 2020-04-09 | Ichnos Sciences S.A. | Oxindole compounds for use as map4k1 inhibitors |
| CN111285872B (zh) * | 2018-12-06 | 2022-05-17 | 北京志健金瑞生物医药科技有限公司 | 吲哚-2-酮衍生物及其制备方法与用途 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001016130A1 (de) * | 1999-08-27 | 2001-03-08 | Boehringer Ingelheim Pharma Kg | Substituierte indolinone als tyrosinkinase inhibitoren |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4476307A (en) * | 1982-09-20 | 1984-10-09 | Pfizer Inc. | Heteroylidene indolone compounds |
| US4966849A (en) * | 1985-09-20 | 1990-10-30 | President And Fellows Of Harvard College | CDNA and genes for human angiogenin (angiogenesis factor) and methods of expression |
| US5217999A (en) * | 1987-12-24 | 1993-06-08 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Styryl compounds which inhibit EGF receptor protein tyrosine kinase |
| AT389506B (de) * | 1988-08-04 | 1989-12-27 | Voest Alpine Maschinenbau | Verfahren und vorrichtung zum graphitieren von kohlenstoffkoerpern |
| ES2064101T3 (es) | 1990-04-02 | 1995-01-16 | Pfizer | Compuestos de acido bencilfosfonico inhibidores de la quinasa de tirosina. |
| US5302606A (en) * | 1990-04-16 | 1994-04-12 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Styryl-substituted pyridyl compounds which inhibit EGF receptor tyrosine kinase |
| WO1992020642A1 (en) | 1991-05-10 | 1992-11-26 | Rhone-Poulenc Rorer International (Holdings) Inc. | Bis mono-and bicyclic aryl and heteroaryl compounds which inhibit egf and/or pdgf receptor tyrosine kinase |
| WO1992021660A1 (en) | 1991-05-29 | 1992-12-10 | Pfizer, Inc. | Tricyclic polyhydroxylic tyrosine kinase inhibitors |
| SK283413B6 (sk) | 1992-08-06 | 2003-07-01 | Warner-Lambert Company | 2-Tioindoly, 2-indolíntióny a polysulfidy, ich selénové analógy a farmaceutické prostriedky na ich báze |
| US5330992A (en) * | 1992-10-23 | 1994-07-19 | Sterling Winthrop Inc. | 1-cyclopropyl-4-pyridyl-quinolinones |
| WO1994010202A1 (en) | 1992-10-28 | 1994-05-11 | Genentech, Inc. | Vascular endothelial cell growth factor antagonists |
| GB9226855D0 (en) | 1992-12-23 | 1993-02-17 | Erba Carlo Spa | Vinylene-azaindole derivatives and process for their preparation |
| US6316635B1 (en) * | 1995-06-07 | 2001-11-13 | Sugen, Inc. | 2-indolinone derivatives as modulators of protein kinase activity |
| US5880141A (en) * | 1995-06-07 | 1999-03-09 | Sugen, Inc. | Benzylidene-Z-indoline compounds for the treatment of disease |
| GB9718913D0 (en) * | 1997-09-05 | 1997-11-12 | Glaxo Group Ltd | Substituted oxindole derivatives |
| DE19824922A1 (de) * | 1998-06-04 | 1999-12-09 | Boehringer Ingelheim Pharma | Neue substituierte Indolinone, ihre Herstellung und ihre Verwendung als Arzneimittel |
| JP2002523455A (ja) | 1998-08-31 | 2002-07-30 | スージェン・インコーポレーテッド | 蛋白質キナーゼ活性の調節剤としての幾何学的に制限された２−インドリノン誘導体 |
| HUP0104973A3 (en) * | 1998-09-25 | 2002-06-28 | Boehringer Ingelheim Pharma | Novel substituted indolinones with an inhibitory effect on various kinases and cyclin/cdk complexes, process for their use and medicaments containing them |
| GB9904933D0 (en) * | 1999-03-04 | 1999-04-28 | Glaxo Group Ltd | Compounds |
| UA75054C2 (uk) * | 1999-10-13 | 2006-03-15 | Бьорінгер Інгельхайм Фарма Гмбх & Ко. Кг | Заміщені в положенні 6 індолінони, їх одержання та їх застосування як лікарського засобу |
| US6762180B1 (en) * | 1999-10-13 | 2004-07-13 | Boehringer Ingelheim Pharma Kg | Substituted indolines which inhibit receptor tyrosine kinases |
| EP1339680A1 (en) * | 2000-09-01 | 2003-09-03 | Glaxo Group Limited | Substituted oxindole derivatives as tyrosine kinase inhibitors |
| AU2002341881B2 (en) * | 2001-09-27 | 2008-05-08 | Allergan, Inc. | 3-(arylamino)methylene-1, 3-dihydro-2h-indol-2-ones as kinase inhibitors |
-
2002
- 2002-09-27 AU AU2002341881A patent/AU2002341881B2/en not_active Ceased
- 2002-09-27 CA CA2461812A patent/CA2461812C/en not_active Expired - Fee Related
- 2002-09-27 WO PCT/US2002/030882 patent/WO2003027102A1/en not_active Ceased
- 2002-09-27 US US10/256,879 patent/US6765012B2/en not_active Expired - Fee Related
- 2002-09-27 EP EP02776036A patent/EP1430048A1/en not_active Withdrawn
- 2002-09-27 US US10/259,703 patent/US20030225152A1/en not_active Abandoned
- 2002-09-27 JP JP2003530690A patent/JP2005508336A/ja active Pending
-
2004
- 2004-02-20 US US10/783,325 patent/US7015220B2/en not_active Expired - Lifetime
- 2004-07-06 US US10/886,213 patent/US7098236B2/en not_active Expired - Lifetime
-
2005
- 2005-09-16 US US11/228,780 patent/US20060025413A1/en not_active Abandoned
- 2005-11-15 US US11/274,681 patent/US7414054B2/en not_active Expired - Lifetime
-
2006
- 2006-03-31 US US11/396,036 patent/US20060194863A1/en not_active Abandoned
-
2010
- 2010-01-25 JP JP2010013326A patent/JP2010116411A/ja active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001016130A1 (de) * | 1999-08-27 | 2001-03-08 | Boehringer Ingelheim Pharma Kg | Substituierte indolinone als tyrosinkinase inhibitoren |
Non-Patent Citations (3)
| Title |
|---|
| Coda A C, et al: "Copper(II) in organic synthesis. V. Influence on the nature of copper(II) complexes of 3-arylaminomethyleneoxindoles...", Gazzetta Chimica Italiana, Societa Chimica Italiana, vol. 117, no. 5, 1987, pages 301-305. * |
| Seshadri S, et al: "Studies on the application of the Vilsmeier-Haack reaction to lactams: Part I...", Indian Journal of Chemistry, Section B: Organic, Incl. Medicinal Publications and Informations Directorate, vol. 7, 1969, pages 667-671. * |
| Wolfbeis O S: "An efficient synthesis of aminoalkylidene derivatives fivemembered active methylene compounds", Monatshefte fur chemie, vol. 112, 1981, pages 369-383. * |
Also Published As
| Publication number | Publication date |
|---|---|
| US20040198720A1 (en) | 2004-10-07 |
| EP1430048A1 (en) | 2004-06-23 |
| CA2461812C (en) | 2011-09-20 |
| US7414054B2 (en) | 2008-08-19 |
| US20060025413A1 (en) | 2006-02-02 |
| US20050228036A1 (en) | 2005-10-13 |
| US7015220B2 (en) | 2006-03-21 |
| WO2003027102A1 (en) | 2003-04-03 |
| CA2461812A1 (en) | 2003-04-03 |
| JP2010116411A (ja) | 2010-05-27 |
| US20030199478A1 (en) | 2003-10-23 |
| JP2005508336A (ja) | 2005-03-31 |
| US20060194863A1 (en) | 2006-08-31 |
| US20060063940A1 (en) | 2006-03-23 |
| US7098236B2 (en) | 2006-08-29 |
| US20030225152A1 (en) | 2003-12-04 |
| US6765012B2 (en) | 2004-07-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2002341881B2 (en) | 3-(arylamino)methylene-1, 3-dihydro-2h-indol-2-ones as kinase inhibitors | |
| AU2002341881A1 (en) | 3-(arylamino)methylene-1, 3-dihydro-2h-indol-2-ones as kinase inhibitors | |
| US8809534B2 (en) | Compounds as tyrosine kinase modulators | |
| JP2021050233A (ja) | ｃ−Ｍｅｔモジュレーターおよびその使用 | |
| US6747025B1 (en) | Kinase inhibitors for the treatment of disease | |
| US6559173B1 (en) | 3-(heteroarylamino)methylene-1,3-dihydro-2H-indol-2-ones as kinase inhibitors | |
| US6699863B1 (en) | Kinase inhibitors for the treatment of disease | |
| US8455529B2 (en) | Kinase inhibitors | |
| US7439371B2 (en) | Indol kinase inhibitors | |
| WO2004050621A2 (en) | Indol derivatives and their use as kinase inhibitors | |
| CN106565682A (zh) | 取代吲哚满酮衍生物及其用途 | |
| WO2003027109A1 (en) | 3-(heteroarylamino)methylene-1, 3-dihydro-2h-indol-2-ones as kinase inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGA | Letters patent sealed or granted (standard patent) | ||
| MK14 | Patent ceased section 143(a) (annual fees not paid) or expired |